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Abstract

ANALYSIS OF THE MECHANISM OF TRANSFERRIN-IRON ACQUISITION BY
NEISSERIA GONORRHOEAE
By Jennifer McMillan Noto
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2008
Major Director: Cynthia Nau Cornelissen, Ph.D.
Professor of Microbiology and Immunology

Neisseria gonorrhoeae is an obligate human pathogen that requires iron for its
survival within the host. N. gonorrhoeae expresses high-affinity iron acquisition systems
to acquire iron from host iron binding proteins. The gonococcal transferrin-iron uptake
system is composed of two transferrin binding proteins, TbpA and TbpB. TbpA is a
TonB-dependent, outer membrane transporter, while TbpB is a surface-exposed
lipoprotein. Unlike TbpA, TbpB is not required for transferrin utilization, but makes the
process more efficient. The precise mechanism by which TbpA and TbpB function to
mediate transferrin-iron uptake has not been fully characterized. However, the

xxii

mechanism of iron acquisition from transferrin is distinct from characterized TonBdependent ferric-siderophore uptake systems. The transferrin-iron uptake system is
unique in two ways: the involvement of the TbpB lipoprotein component and the process
of iron acquisition and internalization. Unlike siderophore transporters, the transferriniron uptake system requires the removal of iron from transferrin for its subsequent
internalization. Based on analogy with characterized TonB-dependent transporters,
TbpA is proposed to consist of two distinct domains: a β-barrel and plug domain.
Previous studies suggest that the plug domain has a specific role in iron internalization
and this study addresses the role of the plug domain in transferrin-iron acquisition. It is
thought that the TbpA plug domain facilitates iron removal from transferrin and
subsequent iron binding and transport. To analyze this, iron binding by the TbpA plug
domain was performed and site-directed substitution mutagenesis of putative ironcoordinating residues was carried out. From these analyses, it can be concluded that the
plug domain binds iron and likely plays an active role in the process of iron
internalization. Mutagenesis revealed specific residues of the plug domain critical for
transferrin-iron uptake, but defects imparted by these mutations were compensated for by
TbpB. Thus, this study also attempts to characterize the compensatory function provided
by TbpB. Through mutagenesis, critical domains involved in the efficiency of
transferrin-iron acquisition were identified. One additional study describes and
characterizes a novel mechanism of TonB-independent transferrin-iron acquisition.
Overall, these studies further elucidate mechanisms utilized by Neisseria gonorrhoeae in
the process of iron acquisition from human transferrin.
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CHAPTER 1 – INTRODUCTION
Neisseria gonorrhoeae and Neisseria meningitidis are both human pathogens in
the Neisseriaceae family. N. gonorrhoeae is the causative agent of the sexually
transmitted disease gonorrhea. The first documented observations of gonorrhea were
made by Hippocrates (460 – 355 BC) (146), and the bacterium N. gonorrhoeae was first
discovered in 1879 by Albert Neisser. Although N. gonorrhoeae was not recognized
until the nineteenth century, gonorrhea has been described since antiquity, with
references made in biblical and other ancient texts (146). Until the advent of antibiotics
in the 1900s, gonorrhea was very difficult to treat and control. To this day, gonorrhea has
still proven difficult to control because of the increasing antibiotic resistance in isolates
throughout the world (33, 34). In addition to the high incidence of antibiotic resistance
(33), the lack of protective immunity and increase in HIV transmission correlated with
gonococcal infection (44, 128) point to the need for development of an effective vaccine
against N. gonorrhoeae.
Neisseria meningitidis is closely related to N. gonorrhoeae and was first described
by Anton Weichselbaum in 1887. N. meningitidis is the causative agent of bacterial
meningitis, which may lead to life threatening bacteremia. Despite the differences in
disease manifestations, the two pathogenic Neisseria share a close evolutionary
relationship (217) and have a very similar repertoire of virulence factors. Therefore,
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experimental observations made in studying N. gonorrhoeae may be applied to N.
meningitidis, and furthermore, the development of an effective vaccine against
gonococcal infections may also provide protection against meningococcal disease.

I. Genus Neisseria
The genus Neisseria belongs to the family Neisseriaceae, which is comprised of
many genera, including Moraxella, Acinetobacter, and Kingella (83, 100). Species
belonging to the genus Neisseria include both obligate human pathogens and normal
human flora. The most well studied of the Neisseria species are the pathogens N.
gonorrhoeae and N. meningitidis. N. gonorrhoeae is the only true pathogen because it is
always associated with the disease state (32), whereas N. meningitidis can be found
among normal human flora.
Neisseria species are Gram-negative diplococci that have adjacent, flattened sides
and range in size from 0.6 to 1.5 μm. Neisseria are classified as either aerobes or
facultative aerobes, with optimal growth conditions between 35oC and 37oC in the
presence 5% CO2. Neisseria species are fastidious microorganisms that require complex
growth media with glucose provided as a carbon source. Consistent with the fact that
most Neisseria species rely on the human host for survival, all species have limited
metabolic capabilities. This limited metabolic potential provides a basis for species
differentiation based on abilities to produce acid from carbohydrates, polysaccharide
from sucrose, and the ability to reduce nitrate. In addition, Neisseria produce a number
of enzymes that allow for species differentiation (83, 100) (Table1).
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II. Neisseria Infection
Both pathogenic Neisseria species are associated with human epithelial mucosa
(136), and despite their close evolutionary relationship (217), meningococci colonize the
nasopharynx, while gonococci primarily infect the urogenital tract. The differences in
disease states and the few differences in virulence factors are likely linked to the different
modes of transmission utilized by N. gonorrhoeae and N. meningitidis.
A. Meningococcal infection
Neisseria meningitidis is a commensal that is spread by respiratory droplets and
colonizes the oro- or nasopharynx of approximately 5 – 30% of the human population
(71). N. meningitidis, in some cases, can be classified as a member of the normal flora
or, in others, can be associated with invasive meningococcal disease. It has been shown
through multilocus sequence typing (MLST) that disease is caused by hypervirulent
lineages of N. meningitidis (123) and that these lineages are vastly underrepresented in
asymptomatic meningococcal carriers (41). Invasive meningococcal disease develops
when meningococci cross the nasopharyngeal epithelium and enter the bloodstream,
resulting in bacteremia. In turn, meningitis results when meningococci cross the bloodbrain barrier, which can occur as a consequence of high level bacteremia (154). Invasive
meningococcal disease usually develops rapidly and has a high rate of fatality between 5
– 15% (86). The rapid disease progression makes prompt diagnosis and intervention
critical for survival of meningococcemia and meningitis.
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Neisseria meningitidis can be classified into thirteen different serogroups, based
on the polysaccharide capsule. Serogroups A, B, C, Y, and W-135 are most commonly
associated with invasive meningococcal disease, with A, B, and C accounting for
approximately 90% of cases worldwide (168). Currently there is an effective tetravalent
vaccine against serogroups A, C, Y, and W-135; however, there is no vaccine against
serogroup B because this capsular polysaccharide lacks immunogenicity. The lack of
immunogenicity occurs through the decoration of serogroup B capsule with host sialic
acid, which is considered a form of molecular mimicry (203). The need for an effective
vaccine against all capsular serotypes is critical in eliminating meningococcal disease
throughout the world.
B. Meningococcal epidemiology
The rate of meningococcal disease in the United States is relatively low, with
approximately 0.9 – 1.5 cases per 100,000 people (189). The rates of meningococcal
disease are highest among infants, but rates drop following infancy and then rise again
during adolescence and early adulthood (190). In addition to fluctuations in disease rate
among different age groups, fluctuations in rates are also observed during seasonal
changes, with rates highest during the winter and early spring in the United States (190).
Meningococcal disease is a much more serious problem in other parts of the world.
Europe has slightly higher rates of disease than the United States, with approximately 0.3
– 7.1 cases per 100,000 people (159). Meningococcal disease occurs in major epidemics
within the African meningitis belt, which includes many sub-Saharan countries. The
rates of disease during these epidemics are 500 – 1000 times the rates seen in the United
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States, with approximately 500 – 1000 cases per 100,000 people (237). Overall,
meningococcal disease is serious and widespread throughout the world. The various
factors that contribute to meningococcal disease and epidemics are complex and not well
understood.
C. Gonococcal infection
Neisseria gonorrhoeae is the causative agent of the sexually transmitted disease
gonorrhea. Gonorrhea is transmitted through sexual contact and causes a localized
infection of the male and female lower urogenital mucosa. In men, gonorrhea typically
presents as an acute urethritis, and epididymitis is a common complication of untreated
urethritis. Although rare in males, other complications result from ascension of
gonococci to the upper genital tract and include prostatitis, posterior urethritis, and
seminal vesiculitis (68). In women, gonococcal infection causes cervicitis and/or
urethritis, but up to 80% of women are asymptomatic and do not seek proper medical
attention (8, 129, 167). It has been shown that 40% of women with localized gonococcal
infection are also anorectally colonized with N. gonorrhoeae (99). Ascension of
gonococci to the upper genital tract can result in pelvic inflammatory disease (PID),
which is seen in 10 – 20% of female infections (82, 236). If left untreated, PID can cause
fallopian tube scarring and can ultimately result in infertility and/or ectopic pregnancy
(150, 202). Disseminated gonococcal infection (DGI) can also occur, but at a relatively
low frequency (0.5 – 3%) and most commonly in young women (68). Classic symptoms
of DGI include dermatitis, tenosynovitis, migratory polyarthritis, and even less common
perihepatitis (120) and endocarditis (92). Additional primary sites of gonococcal
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infection include the rectum, pharynx, and conjunctiva. Gonococcal conjunctivitis is a
localized infection of the adult eye that can result in corneal scarring and without
immediate treatment can lead to loss of vision (143, 221). Gonococcal infection can be
transferred from mother to neonate during vaginal childbirth, causing neonatal
conjunctivitis. Although not a significant problem in the United States, this infection
remains a very common cause of blindness in developing countries (108). The serious
sequelae resulting from gonococcal infection, the lack of protective immunity, and the
correlation with HIV transmission (44, 128), all point to the need for an effective vaccine
against N. gonorrhoeae.
D. Gonococcal epidemiology
Infection by Neisseria gonorrhoeae is a major health concern throughout the
world. In 1998, the World Health Organization reported that there were 62.2 million
cases of gonorrhea worldwide (238). The estimated number of cases in the United States
reached approximately 360,000 cases in 2006, making gonorrhea the second most
frequently reported communicable disease following chlamydial infection (33).
Although the rates of gonorrhea declined 74% from 1975 to 1997, the rates steadily
increased again, with the number of cases reaching 121 per 100,000 people in 1998 (32).
Reporting of gonococcal cases is typically lower than the actual incidence of disease
particularly due to underreporting and asymptomatic gonococcal infection in women.
The high rates of gonococcal infection seen throughout the world are a serious
cause for concern. Gonorrhea has huge health implications in regard to PID and the role
gonococcal infection plays in facilitating HIV infection (44, 128). The continuing
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emergence of antibiotic resistant N. gonorrhoeae is of increasing concern for the control
and prevention of gonorrhea. Recent reports of antibiotic resistance in N. gonorrhoeae
show that there is still a high prevalence of isolates resistant to both penicillin and
tetracycline, presence of multi-drug resistant strains, and an emergence of
fluoroquinolone resistance (33). In addition, the Center for Disease Control and
Prevention recommended in 2007 that fluoroquinolones should no longer be used for
treatment of gonococcal infection (34). Currently, third generation cephalosporins are
the treatment of choice against gonorrhea, but decreased susceptibility has been observed
(33), which suggests that it is only a matter of time before resistance develops to all
currently available antibiotic therapies. In addition to the health implications resulting
from gonococcal infection, the increasing rates of resistance seen in N. gonorrhoeae
again point to the need for the development of an effective vaccine.

III. Neisseria Virulence Factors
Pathogenic Neisseria express a wide range of virulence factors that contribute to
pathogenesis within the human host. A number of these factors contribute to initial
adherence to mucosal epithelium, while other adhesins facilitate more intimate adherence
with specific host cell receptors. These interactions facilitate invasion and transcytosis
across epithelial cells, which allows for interaction with endothelial and various immune
cells. These interactions can ultimately lead to entry into the bloodstream and
dissemination to distal sites. During this process there are many virulence factors
involved in immune evasion, extracellular and intracellular survival, and disease
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progression. These virulence determinants and their roles in gonococcal and
meningococcal pathogenesis are discussed below.
A. Capsule
Polysaccharide capsule is one well-characterized virulence factor that is found in
N. meningitidis, but absent in N. gonorrhoeae (68). Thus, capsule is likely one of the
main virulence determinant that facilitates the different mode of transmission, disease
progression, and disease outcome observed with meningococcal infection. N.
meningitidis expresses 13 different capsule types, which differ in the polysaccharide
composition. Meningococcal capsule is subject to high-frequency phase variation and
various sialic acid modifications, which have both been shown to be important in
resistance to phagocytosis and complement-mediated killing (68). The diversity of
capsular polysaccharides in addition to the variations within each capsular serogroup
make capsular polysaccharide a dynamic virulence factor in the pathogenesis of N.
meningitidis.
B. Pilus
To initiate infection, pathogenic Neisseria must adhere to the mucosal epithelium
in a step known as initial adherence. Type IV pilus is critical for the colonization of the
mucosal nasopharynx and urogenital tract. In the absence of pili, gonococci are unable to
initiate infection upon human challenge (95, 96). Type IV pili are long filamentous
structures that extend from the gonococcal and meningococcal cell surface and facilitate
binding to host mucosal epithelium. The long pili allow gonococci and meningococci to

9

overcome the negative electrostatic barrier that exists between bacterial and host cells to
allow for initial attachment (80).
The type IV pilus is composed of two subunits: monomeric pilin subunits (PilE)
that form the pilus fiber and PilC, the pilus tip adhesin (191). Pili have been shown to
mediate many different cellular interactions with epithelial cells, endothelial cells,
granulocytes, macrophages, and erythrocytes (101, 193, 196, 224, 227). PilC has been
shown to be an important factor in host cell interactions and facilitates interaction with
both epithelial and endothelial cells (153). PilC mutants are unable to interact with these
cells, and purified PilC prevented piliated gonococci from interacting with epithelial cells
in vitro (195).
Type IV pili of pathogenic Neisseria are antigenic and produce a local antibody
response that blocks attachment of bacteria to epithelial cells (90, 127, 219); however,
expression of pilus is subject to both phase and antigenic variation, which makes it a poor
vaccine candidate. Phase variation of pilus results from RecA-independent frame shifting
known as slipped-strand mispairing, while antigenic variation results from RecAdependent, non-reciprocal gene conversion (103). Slipped-strand mispairing occurs
during DNA replication, when DNA polymerase skips or adds bases in the poly cysteine
tract of pilE, causing a frame shift and gene expression to be turned off (103). Phase
variation occurs at a relatively high frequency of 10-4 per cell generation (103, 245).
Antigenic variation of pilus results from the non-reciprocal exchange of DNA sequences
from one of several silent pilS loci into the pilE expression locus (73, 134, 135, 199). In
addition to phase and antigenic variation, pilin is also subject to posttranslational
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modifications through phosphorylation and glycosylation (205, 227). The receptor
responsible for pilus interactions with host cells has not been identified and the only
receptor (93) that has been implicated in this interaction is subject to much controversy
(125).
C. Opacity proteins
The neisserial opacity proteins (Opa) were identified and named for the color and
opacity that they impart on gonococcal colonies (87, 212). Opacity proteins are integral
outer membrane proteins that have been associated with Neisseria virulence and host cell
interaction. Opas are linked to N. gonorrhoeae virulence because gonococci recovered
from urogenital, cervical, and rectal infections always express at least one Opa protein
(213). In addition, gonococcal strains, not expressing Opas, used in volunteer infection
studies are always recovered following infection expressing these proteins (89). These
studies point to the fact that opacity proteins are required for survival and virulence in
vivo. Any single gonococcal strain can possess up to eleven distinct opa alleles that
encode antigenically distinct Opa variants, while meningococcal strains only possess up
to four distinct opa alleles (13, 106). Opacity proteins from both N. meningitidis and N.
gonorrhoeae are subject to high-frequency phase variation that in N. gonorrhoeae results
in the expression of zero to four Opas at any one time (17). This phase variation occurs
via slipped-strand mispairing in which the number of CTCTT repeats in a poly CTCTT
tract vary and cause frame shifts that result in differential expression of none, one, or
multiple Opas at one time (152, 204).
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Opacity proteins have also been characterized as factors involved in intimate
attachment to host cells. Opas have been shown to facilitate binding and invasion of host
cells through interactions with surface heparan sulfate proteoglycans (HSPG) as well as
carcinoembryonic antigen-related cell adhesion molecules (CEACAM) on various cell
and tissue types (68). Several of the eleven different Opas expressed by N. gonorrhoeae
bind to HSPGs (39, 106, 223) and one in particular has been shown to mediate intimate
adherence that results in receptor-mediated endocytosis into epithelial cells (106, 230,
231). This Opa protein has also been shown to mediate binding and promote invasion of
endothelial cells and fibroblasts, although in a less efficient manner than seen with
epithelial cells (67).
CEACAMs are differentially expressed on a variety of cell types (9, 173, 216)
and Opas have been shown to interact with a number of CEACAMs (19, 69). Opamediated binding and invasion has been observed in many cells, including epithelial,
endothelial, and phagocytic cells and these events ultimately leads to CEACAMdependent intracellular signaling. Although Opa-CEACAM interactions are important
for gonococcal cell tropisms, this interaction is also important in the down regulation of
the host immune response through the suppression of T-cell activation and proliferation,
inhibition of antibody production, and induction of B-cell apoptosis (21, 164)
D. Opc
Opc is a neisserial outer membrane adhesin that is similar in size to the opacity
proteins, but structurally and antigenically distinct. Opc was originally identified as a
meningococcal-specific protein, but is also found in N. gonorrhoeae (132). The majority
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of work done on Opc has been in the meningococcus, but its role in intimate adherence
and invasion is important to consider for N. gonorrhoeae. Opc has been shown to
interact with epithelial and endothelial cells (54, 133, 225). Opc interaction with
endothelial cells occurs via αvβ3 integrin in a vitronectin-dependent fashion (226). Opc
likely serves as another adhesin and invasin important for Neisseria pathogenesis.
E. Porins
Porins are the most abundant proteins on the outer membrane of Neisseria. They
form hydrophilic pores that allow for the passive diffusion of small nutrients (molecular
weight ≤ 600 daltons) across the outer membrane (158). Porins have a variety of
different cellular functions that contribute to the pathogenesis of Neisseria. Porin has
been shown to translocate into eukaryotic cytoplasmic and phagosomal membranes
(230). Once inserted in the eukaryotic membranes, porins are regulated by the host cell
(192), which suggests that they have characteristics of voltage-dependent anion channels.
Once porins form pores in eukaryotic membranes, they cause rapid calcium influx and
ultimately induce cellular apoptosis (148, 149). Porins also have effects on the host cell
phagocytic response, by interference with PMN signaling, inhibition of degranulation,
down regulation of opsonin receptor-mediated phagocytosis, and modulation of
phagosomal maturation (16, 75, 147).
N. meningitidis expresses two types of porin, PorA and PorB, while N.
gonorrhoeae only expresses one porin, PorB. PorB of both pathogenic Neisseria have
two antigenically distinct serotypes, designated PIA and PIB. Expression of PorBIA
(PIA) is known to cause increased gonococcal serum resistance and is correlated with
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disseminated gonococcal infection (142). Serum resistance mediated by PIA is
attributable to its ability to bind complement factors, Factor H and C4 binding protein,
and thereby prevent complement-mediated killing (178, 179). Thus, porins are important
in basic nutrient acquisition as well as immune modulation and evasion in the pathogenic
Neisseria.
F. Lipooligosaccharide
Lipopolysaccharide or LPS is a major component of the Gram-negative outer
membrane. LPS is comprised of three parts: lipid A, which is embedded in the outer
membrane, the core polysaccharide, and the O-antigen side chains. Neisserial LPS can
be distinguished from enteric LPS because of its highly-branched core oligosaccharide
structure and lack of repetitive O-antigen side chains. Thus, LPS from Neisseria species
is called lipooligosaccharide or LOS. LOS is an endotoxin and a major virulence factor
involved in the inflammatory response seen during Neisseria infection. LOS, like many
other virulence factors of pathogenic Neisseria, is subject to high-frequency variation.
Variation in LOS occurs at the α side chains within the core polysaccharide, where sugar
residues are added by various glycosyl transferases. These enzymes are subject to
slipped-strand mispairing at poly glycine tracts, which causes variations in expression
patterns. Differential expression of the glycosyl transferases, leads to overall changes in
LOS size, structure, and carbohydrate composition (52, 241). In addition, LOS is subject
to post-translational modification in vivo, which is known to enhance Neisseria serum
resistance. Sialylation of LOS occurs in vivo by gonococcal and meningococcal
sialyltransferases that utilize host derived cytidine 5’-mono-phospho-N-acetylneuraminic

14

acid (CMP-NANA) as a sialyl donor (124). This modification enhances gonococcal and
meningococcal survival in vivo through inhibition of complement deposition (180) and
phagocytic killing (141). Sialylation of LOS with host CMP-NANA represents another
example of molecular mimicry that aids in survival of Neisseria in the human host.
Additionally, LOS sialylation protects Neisseria against PorB-specific bactericidal
antibodies (59).
G. Reduction-modifiable protein
Reduction-modifiable protein (Rmp) is a gonococcal outer membrane protein
found in all gonococcal isolates and is named based on the observed molecular weight
shift following reduction in SDS-PAGE (65). Rmp, an OmpA homolog (66), is often
found in association with LOS and PorB in the outer membrane (81, 130) and is highly
conserved between strains (91, 239). Rmp-specific antibodies serve as blocking
antibodies that protect gonococci from LOS- and PorB-specific bactericidal antibodies
(151, 185). In fact, Rmp antibodies actually increase host susceptibility to gonococcal
infection (171).
H. IgA protease
Pathogenic Neisseria secrete a serine IgA protease that has a high specificity for
human IgAI antibodies. IgAI is a specific subtype of IgA and is the most prominent IgA
antibody found in mucosal secretions (194). Therefore, gonococci and meningococci
come in contact with IgAI antibodies during localized infection and are able to cleave the
Fab antigen binding fragment from the Fc effector domain. This cleavage event
essentially decorates Neisseria with Fab, which aids in masking the immunodominant,
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surface epitopes from host bactericidal antibodies (68). Neisserial IgA protease also
cleaves human lysosome/late endosome associated membrane protein 1 (LAMP-1) and
this cleavage event is important for gonococcal survival and growth within epithelial cells
(79, 116). Not only does IgA protease aid in colonization at mucosal surfaces, but it also
appears to have a significant role in intracellular survival.

IV. Iron and Pathogenesis
A. Iron
Iron is one of the most abundant elements on the earth and is essential for the
survival of virtually all organisms (25). Iron has a versatile redox potential, and can exist
in the reduced ferrous (Fe2+) form or the oxidized ferric (Fe3+) state. Under aerobic
conditions, ferrous iron (Fe2+) is highly unstable and through the Fenton reaction is
converted to ferric iron (Fe3+) with the production of toxic, reactive oxygen species:
Fe2+ + H2O2 → Fe3+ + OH· + OH−
The reactivity and toxicity of iron creates an environment in which iron sequestration is
critical within the human host. Although iron is very abundant in nature, it exists in an
inaccessible form due to its extreme insolubility. This property of insolubility creates an
iron-limiting environment in the human host, with a concentration of free, ferric iron
(Fe3+) of 10-18 M (29), which is far below the nutrient requirement for survival of
microorganisms (232). Within the human host, this concentration is even lower as a
result of host iron binding proteins sequestering free iron from the environment (182).
All microorganisms require iron, with the exception of only two known bacterial genera,
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Lactobacillus (5) and Borrelia (172). Iron is critically important as an electron carrier in
microbial oxidative metabolism and as the catalytic center of a variety of essential
enzymes. As a result, pathogenic microorganisms have evolved mechanisms to acquire
iron from host iron binding proteins to survive and persist within the human host.
B. Pathogenic mechanisms for iron acquisition
There are many mechanisms by which microorganisms acquire iron from the
human host. Many microorganisms produce and secrete siderophores, low-molecularweight iron-chelating molecules, during iron stress to scavenge iron from their
environments (155, 156). Siderophores function to specifically bind, solubilize, and
deliver iron via bacterial ferric-siderophore uptake systems. Some bacteria can obtain
iron through the expression and secretion of ferric reductases, which reduce ferric iron
(Fe3+) to the more soluble ferrous (Fe2+) form for utilization (51, 197). These reductases
have also been shown to remove iron from host iron binding proteins through this
reduction event (51, 197). Other bacteria have receptor-mediated mechanisms to
scavenge and utilize iron from heme, hemoproteins, and other host serum proteins, such
as lactoferrin and transferrin. The human host goes to great lengths to sequester iron in
an attempt to make free iron inaccessible, and pathogenic microorganisms have
developed a variety of different mechanisms to bypass this iron sequestration for
survival. These mechanisms of host iron sequestration and the pathogenic mechanisms in
which bacteria acquire iron from the human host are discussed in the next two sections.
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V. Iron Sources in the Human Host
A. Ferric and ferrous iron
Ferric iron (Fe3+) is the major form available in aerobic environments, but is
highly insoluble in the form of ferric hydroxides. Ferrous iron (Fe2+), however, is the
predominant form under anaerobic or reducing conditions. Although not typically
present in high concentrations within the human host, soluble, ferrous iron (Fe2+) can
diffuse freely across Gram-negative outer membranes via porins. Subsequently, iron is
transported through the cytoplasmic membrane by ABC ferrous iron (Fe2+) transporters,
which are conserved among many bacterial species (94).
B. Ferritin
Ferritin is the major cytoplasmic iron storage protein within the human host.
Ferritins function intracellularly to provide iron during iron shortages and also protect the
host from the toxic effects of iron accumulation. Ferritin consists of 24 subunits that
form a icosahedron structure (30) that has a capacity for harboring more than 4000 ferric
iron (Fe3+) atoms (1, 2, 181). Although ferritins have not been shown to be a substantial
iron source for bacterial pathogens, they constitute a major intracellular iron source.
C. Heme & heme binding proteins
a. Heme
Heme is an iron-containing porphyrin ring that is highly toxic to cells and as a
result, is scarcely found free in the human host. Despite its scarcity in the host
environment, heme does serve as an iron source for a variety of bacterial pathogens.
These microorganisms express specific, high-affinity uptake systems to acquire heme-
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iron from the human host. However due to its toxicity, free heme exists at very low
concentrations because it is sequestered by the host hemoproteins: hemoglobin,
haptoglobin, and hemopexin.
b. Hemoglobin
Hemoglobin is found in red blood cells and functions as an oxygen carrier in the
human host. It is tetrameric in structure and each subunit binds heme. Hemoglobin can
exist in one of three states: (1) methemoglobin, which is oxidized and contains ferric iron
(Fe3+); (2) oxyhemoglobin, which is the oxygen carrying form; or (3)
carboxyhemoglobin, which is reduced and contains ferrous iron (Fe2+). Many bacterial
species express hemoglobin-specific heme uptake systems for the acquisition of hemeiron complexes.
c. Haptoglobin
Haptoglobin is a host serum glycoprotein that binds hemoglobin when it is
released into the serum following hemolysis. The hemoglobin-haptoglobin interaction
occurs at such a high affinity in the host that dissociation only occurs through degradation
of the protein complex in the liver. It has been shown that pathogenic Neisseria (112,
115) and Haemophilus influenzae (122, 145) are able to utilize the hemoglobinhaptoglobin complex as a heme-iron source through receptor-mediated events.
d. Hemopexin
Hemopexin is another host serum glycoprotein that binds heme with a high
affinity (165). Hemopexin functions to remove free heme from the serum and transport it
to the liver, where apopexin is recycled following release of heme intracellularly. To
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date, Haemophilus influenzae has been the only bacterium shown to specifically bind and
utilize hemopexin as a source of heme (78).
D. Lactoferrin
Lactoferrin is an iron binding glycoprotein found in mucosal secretions among
many other places. It is found in highest concentration in breast milk, but is also present
in secondary granules of neutrophils and various other secretions (26). The lactoferrin
structure consists of two highly homologous lobes that both have deep binding clefts that
function in ferric iron (Fe3+) coordination (3). Lactoferrin is similar to transferrin, but has
two features that make it distinct. Those features include its higher affinity for iron and
its higher isoelectric point (pI) (26). Lactoferrin functions primarily in iron chelation to
protect the host from the toxic effects of iron accumulation. However, lactoferrin has
also been attributed to a large number other functions unrelated to its iron binding
capacity (26, 27). One of importance is its antimicrobial properties mediated by both
full-length lactoferrin as well as small, cleaved lactoferrin peptide fragments (26, 240).
Lactoferrin plays an important role in the host through both its immunoregulatory
functions (26) and iron sequestering ability. Many bacterial pathogens have evolved
specific and efficient mechanisms to acquire iron from lactoferrin within the human host.
E. Transferrin
Transferrin is the most abundant iron transport protein found in the human host.
It is an 80 kDa glycoprotein found in high concentrations in serum, lymph, and seminal
fluid. Transferrin has two major functions in the host: (1) iron binding for transport
throughout the human body and (2) protecting the host from iron-mediated toxicity.
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Similar to lactoferrin, transferrin has a high affinity for iron, with an association constant
that has been reported as high as 1031 M (2). The structure of transferrin shows that it is
bi-lobed and both lobes function in high-affinity iron coordination (88). However, in
vivo, transferrin is only about 30% saturated with iron (2). Ferric iron (Fe3+) is
hexacoordinated in the lobes of transferrin by two tyrosines, a histidine, an aspartic acid,
a carbonate, coordinating anion, and a hydroxyl group from water (88). Despite the highaffinity coordination of iron, many bacterial pathogens are able to acquire iron from
transferrin within the human host.

VI. TonB-Dependent Iron Acquisition
The majority of pathogenic mechanisms to obtain iron from the human host are
classified as TonB-dependent iron acquisition systems. The components of TonBdependent iron uptake include, but are not limited to, an integral, outer membrane protein
that transports iron/iron complexes through the outer membrane, a TonB protein complex
that harnesses energy for the process of iron internalization, and a periplasmic iron
binding protein (PBP) that shuttles iron/iron complexes to an ABC transporter within the
cytoplasmic membrane. Various mechanisms of TonB-dependent iron acquisition have
been identified and these systems are discussed (Figure 1).
A. Siderophore-mediated iron acquisition
Siderophores are low-molecular-weight, high-affinity iron chelators of which
more than 500 have been identified (181). They are divided into three major classes
based on the structure and chemical nature of iron coordination. Siderophores are
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classified as catecholates, hydroxamates, and carboxylates; however, this classification
scheme is becoming more complex with new information on siderophores that have
structural and chemical features from more than one class (182). These molecules
specifically bind ferric iron (Fe3+) with a high affinity and rarely bind the ferrous (Fe2+)
form. Ferric iron is complexed in a 1:1 ratio with each siderophore and is typically found
in a hexacoordinated state, which forms an octahedral structure in aqueous solution (182).
Interestingly, ferric-siderophores have a wide range of affinities for iron, with
dissociation constants ranging from 1022 to 1050 (181), over 30 orders of magnitude
differences between some (139). These relative affinities for iron are sufficient for
siderophore-mediated removal of iron from human ferritin, lactoferrin, and transferrin,
but not the various hemoproteins (181).
Siderophores are synthesized and secreted by microorganisms to scavenge iron
from the environment (228). Once ferric iron (Fe3+) is bound and mobilized by
siderophores, it becomes accessible by one of two ways: (1) iron is released from the
siderophore complex through a reduction at the bacterial cell surface, whereby iron is
taken up by the cell (51) or (2) the entire ferric-siderophore complex is internalized by a
TonB-dependent receptor-mediated event (139). However, bacterial systems of
reduction-mediated iron removal from siderophores are less well known and the receptormediated events are considered the major route of siderophore-mediated iron acquisition
(139).
Ferric-siderophore uptake (Figure 1), like all TonB-dependent transporters,
requires TonB energization and an outer membrane transporter to facilitate uptake
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through the outer membrane. The TonB complex is composed of three proteins: TonB,
which is embedded in the cytoplasmic membrane and spans the periplasmic space and
ExbB and ExbD, which are both embedded in the cytoplasmic membrane. These
proteins work together to harness the proton motive force of the cytoplasmic membrane
to energize TonB, which is thought to promote its interaction with specific outer
membrane transporters and facilitates ferric-siderophore uptake (139). It also requires a
periplasmic iron binding protein (PBP) and an ABC transporter for movement across the
periplasm and through the cytoplasmic membrane, respectively.
Many of these TonB-dependent, outer membrane transporters have been
crystallized and their overall structures, shown in Figure 2, are very similar (28, 40, 42,
43, 119, 244). These structures show the presence of two distinct domains: (1) a Cterminal β-barrel consisting of 22 β-strand transmembrane-spanning domains and (2) an
N-terminal plug domain that folds up with the β-barrel. Mutagenesis (35, 36) and
disulfide tethering (58) of the plug domain, have revealed that the plug domain undergoes
conformational rearrangement that allows for ferric-siderophore transport through the
outer membrane. This conformational change is thought to occur following interaction
with TonB and results in siderophore translocation through the outer membrane (166,
200).
Following ABC-mediated transport through the cytoplasmic membrane, the
ferric-siderophore gains access to the bacterial cytoplasm. Within the cytoplasm, there
are two known mechanisms that result in iron release from siderophore complexes. The
first involves the reduction of ferric iron (Fe3+) to ferrous iron (Fe2+) by cytoplasmic
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ferric-siderophore reductases (139). The second involves specialized enzymes that
promote hydrolysis, resulting in destabilization of the siderophore and release of iron
(139). Overall, these mechanisms of TonB-dependent siderophore-mediated iron
acquisition are utilized by many pathogenic microorganisms to meet their iron
requirements in the midst of severe iron starvation within the human host.
B. Non-siderophore-mediated iron acquisition
a. Heme and hemoproteins
Many pathogenic bacteria utilize heme as an iron source within the human host.
Similar to iron, heme is cytotoxic and thus sequestered by host hemoproteins,
hemoglobin, haptoglobin, and hemopexin. One mechanism pathogens utilize to gain
access to heme within the host is the secretion of exotoxins that cause cell lysis (109, 162,
170, 201, 206), which results in the release of intracellular heme and hemoproteins. Once
heme and/or hemoproteins are accessible, pathogens utilize two mechanisms for
acquiring heme (reviewed in (229)). The first involves direct uptake of heme from host
hemoproteins through TonB-dependent outer membrane transporters, as shown in Figure
1 (169). This process resembles the mechanism described for siderophore-mediated iron
acquisition, requiring an outer membrane transporter, periplasmic binding protein (PBP),
and cytoplasmic membrane-associated ABC transporter. However, unlike ferricsiderophore transporters these hemoprotein receptors consist of two proteins that are both
required for heme acquisition and uptake. Briefly, the hemoprotein is bound to the outer
membrane receptor, heme is removed, and transported through the outer membrane in a
TonB-dependent step. Subsequently, heme is received and bound by a periplasmic heme
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binding protein (PBP) and shuttled to the ABC transporter, which facilitates uptake into
the bacterial cytoplasm. Once heme reaches the cytoplasm, it is degraded and iron is
released and utilized by the cell.
The second mechanism by which bacteria utilize heme is through the secretion of
hemophores, which scavenge heme from the environment and deliver it back to specific
TonB-dependent receptors for internalization (reviewed in (55)). Once the hemehemophore complex binds the receptor, the mechanism of heme uptake is essentially
identical to that for the process involved in hemoprotein-heme acquisition described
previously.
b. Lactoferrin and transferrin
Many pathogenic bacteria express high-affinity receptors for human lactoferrin
and transferrin binding (70). These receptors not only function in lactoferrin/transferrin
binding, but also TonB-dependent iron transport. Thus, both of these receptors have two
ligand specificities, one for lactoferrin/transferrin and another for iron. In contrast to the
ferric-siderophore transporters, both lactoferrin- and transferrin-iron acquisition systems
involve two protein components: an integral, outer membrane protein and a surfaceexposed lipoprotein. In both systems, the outer membrane transporter (LbpA/TbpA)
functions in lactoferrin or transferrin binding as well as iron transport, while the lipidated
protein (LbpB/TbpB) functions only in ligand binding. The process of lactoferrin- and
transferrin-mediated iron acquisition is thought to be similar to the process described in
siderophore-mediated iron acquisition (Figure 1). However, there are two major
differences in the lactoferrin- and transferrin-iron acquisition systems that make them
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unique from characterized TonB-dependent siderophore transporters. Firstly, the
lipoprotein components are not present in siderophore-mediated iron acquisition systems.
Secondly, the mechanism of iron internalization likely differs in that both lactoferrin and
transferrin must be stripped of iron in the process of transport, whereas, ferricsiderophore complexes are transported without this iron removal step. Although the
crystal structures of these integral, outer membrane proteins and the lipoproteins have not
been solved, the outer membrane transporters are thought to look very similar to
crystallized siderophore transporters (Figure 2), consisting of two distinct domains.

VII. Iron Acquisition Systems in Pathogenic Neisseria
A. Siderophore utilization
Neisseria do not produce any known siderophores (6, 131, 235), but have been
shown to utilize siderophores produced by other microorganisms (31, 234). The
receptors for utilization of these xenosiderophores have not been identified; however, a
number of putative receptors have been, which have significant homology to
characterized E. coli TonB-dependent siderophore transporters (220). The possible role
of these putative transporters in xenosiderophore utilization has yet to be determined. To
date, there has been only one siderophore receptor, FrpB/FetA, in N. gonorrhoeae linked
to ferric-enterobactin binding, but its specific role in ferric-enterobactin uptake has not
been shown (31). Although ferric-siderophore utilization is a major mechanism of iron
acquisition for many bacterial pathogens, it does not appear to play a significant role in
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Neisseria iron acquisition. As a result, pathogenic Neisseria express high-affinity iron
acquisition systems to acquire iron from host iron binding proteins.
B. Hemoprotein utilization
Pathogenic Neisseria are not able to use hemopexin, myoglobin, or other heme
sources, such as albumin, catalase, or cytochromes (23), but can utilize free heme in a
TonB-independent mechanism (209). Through TonB-dependent mechanisms, pathogenic
Neisseria are able to utilize hemoglobin and haptoglobin as heme-iron sources through
the expression of HpuA and HpuB (38, 112, 114, 115). Similar to the lactoferrin- and
transferrin-iron acquisition systems, the hemoglobin and haptoglobin utilization system
has two components. HpuB is the TonB-dependent, outer membrane heme transporter,
while HpuA is the surface-exposed lipoprotein (114). Unlike the lactoferrin and
transferrin systems, both components are required for hemoglobin- and haptoglobinmediated heme uptake (115). Also unlike the components of the lactoferrin and
transferrin utilization systems, the hemoglobin and haptoglobin utilization components,
HpuA and HpuB, are subject to high-frequency phase variation, which occurs through
slipped-strand mispairing at a poly glycine tract within the hpuAB locus (113).
N. meningitidis, but not N. gonorrhoeae, also expresses another TonB-dependent
receptor, HmbR, which functions in only hemoglobin utilization (110, 207, 208). This
hemoglobin utilization system is comprised of only one outer membrane receptor, HmbR,
unlike the two component system for hemoglobin and haptoglobin utilization (110, 207,
208). Similar to the components of the hemoglobin and haptoglobin utilization system,
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HmbR is also subject to high-frequency phase variation though slipped-strand mispairing
at a poly glycine tract in the hmbR locus (113, 186).
C. Lactoferrin utilization
Neisseria species are able to use lactoferrin as an iron source in the human host
(6, 18, 111, 131, 137). However, only about 50% of gonococcal isolates are able to
utilize this iron source, which indicates that lactoferrin may not be required for survival
of N. gonorrhoeae at mucosal surfaces or in disseminated infection (137). Lactoferrin
utilization is mediated by the lactoferrin binding proteins, LbpA and LbpB (14, 15, 198).
LbpA is a TonB-dependent integral, outer membrane transporter, required for lactoferrinmediated iron acquisition. However, LbpB is a lipid-modified, surface-exposed protein
that is not essential for lactoferrin utilization. This system is thought to function similarly
to other TonB-dependent iron acquisition systems and is shown in Figure 1.
D. Transferrin utilization
Among the many iron acquisition systems of pathogenic Neisseria, the
transferrin-iron acquisition system is likely important during most stages of Neisseria
pathogenesis. Although the transferrin- and lactoferrin-iron acquisition systems are very
similar, they only function in specifically binding transferrin and lactoferrin, respectively.
Unlike the lactoferrin utilization system, the transferrin-iron acquisition system is
expressed by all clinical isolates (138), which implicates its importance in virulence. In
addition, the transferrin-iron uptake system is not subject to high-frequency phase
variation as is seen in the hemoglobin, haptoglobin, and lactoferrin utilization system.
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Similar to the other iron acquisition systems in Neisseria, the transferrin-iron acquisition
system is composed of two transferrin binding proteins (TbpA and TbpB).
The transferrin binding proteins are encoded by a bicistronic operon with tbpB
upstream of tbpA (188). The two genes are separated by an 86 base pair intergenic region
that is thought to form a putative, secondary stem loop structure in the mRNA (188).
This region is thought to be involved in the 2:1 ratio of tbpB and tbpA transcripts (188).
Although there are likely many regulatory mechanisms involved, it has been shown that
expression of the transferrin binding proteins is regulated by the ferric uptake regulator
(Fur), whereby expression is repressed during iron replete conditions and derepressed
under iron deplete conditions (188).
TbpA and TbpB are maximally expressed under iron stress and can function
specifically and independently in high-affinity transferrin binding. TbpA is a TonBdependent, integral, outer membrane protein that is critical for transferrin-mediated iron
acquisition. TbpB, on the other hand, is a surface-exposed lipoprotein that is not
essential for iron uptake. TbpB not only binds transferrin but also discriminates between
the apo and holo forms of transferrin, with a preference for holo-transferrin (20, 50, 183,
184). Although not required for transferrin-mediated iron acquisition, TbpB is known to
make the process more efficient.
Although the crystal structure has not been solved, TbpA has significant
homology to characterized TonB-dependent siderophore transporters (48), of which the
structures are known (Figure 2). Based on these crystal structures, a TbpA twodimensional, topological model has been predicted (Figure 3), in which TbpA is thought
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to look very similar to TonB-dependent transporters. TbpA is proposed to have two
distinct domains: (1) a C-terminal β-barrel pore comprised of 22 β-strand
transmembrane-spanning domains and (2) an N-terminal globular plug that is predicted to
fold up and occlude the β-barrel. As mentioned, TbpA is required for transferrinmediated iron acquisition and functions not only in transferrin binding, but also iron
transport. Following TbpA-transferrin binding, it is hypothesized that TbpA removes
iron from transferrin and transports iron through the outer membrane in a TonBdependent step (Figure 1). It is known that TonB associates with TbpA via a TonB box
of the plug domain (97). This interaction is thought to promote a conformational change
in TbpA that allows for iron removal from transferrin and transport through the TbpA βbarrel. Although TbpB is not required for this iron internalization event, it does make the
process more efficient, for in its absence approximately 50% of wild-type is observed (4).
There is much known about the mechanisms of TonB-dependent siderophore
transport, but the mechanism of TonB-dependent transferrin-iron uptake is less well
known. This system represents a novel TonB-dependent transporter because the unique
mechanism of iron acquisition and the involvement of a secondary, lipoprotein
component. Characterized siderophore transporters are known to bind and internalize
ferric-siderophore complexes, whereas the transferrin-iron acquisition system must bind
holo-transferrin, remove and transport iron through the outer membrane, and ultimately
release apo-transferrin at the surface. These two features make the mechanism of
transferrin-mediated iron acquisition unique and thus important for investigation.
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VIII. Objectives
The goal of the work described here was to further characterize the mechanism of
transferrin-mediated iron acquisition by N. gonorrhoeae. This was accomplished by
three major objectives. The first involved analysis of the TbpA plug domain in TonBdependent transferrin-iron acquisition and its overall contribution to iron binding and
transport through the TbpA β-barrel. The second objective included analysis of both
TbpA and TbpB, with the goal of identifying specific regions of both proteins required
for transferrin-mediated iron acquisition. The third objective, although more distantly
related to the first two, involved analysis of a TonB-independent mechanism of
transferrin-mediated iron acquisition that required TbpA and TbpB. Although different,
each study addressed features of TbpA and TbpB and their specific involvement in iron
acquisition from human transferrin and provided insight into the transferrin-iron
acquisition system of Neisseria gonorrhoeae. These studies are important in fully
dissecting the mechanisms of transferrin utilization used by the pathogenic Neisseria and
also shed light on the vaccine potential of the transferrin binding proteins, TbpA and
TbpB.
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Table 1. Biochemical tests for differentiation of Neisseriaceae

Species

Acid from
G M S F

N. gonorrhoeae
N. meningitidis
N. lactamica
N. polysaccharea
N. cinerea
N. flavescens
N. mucosa
N. subflava

+
+
+
+
−
−
+
+

−
+
+
+
−
−
+
+

N. sicca
N. elongata
M. catarrhalis
K. denitrificans

+
−
−
+

+
−
−
−

−
−
−
−
−
−
+
+
−
+
−
−
−

−
−
−
−
−
−
+
+
−
+
−
−
−

L

−
−
+
−
−
−
−
−
−
−
−
−

Polysaccharide
from S

Nitrate
reduction

Oxidase

Catalase

−
−
−
+
−
+
+
+
−
+
+
−
−

−
−
−
−
−
−
+
−

+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+

−
−
+
+

+
+
+
+

+
−
+
−

Table adapted from Center for Disease Control and Prevention website
Abbreviations: G, glucose; M, maltose; S, sucrose; F, fructose; L, lactose
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Figure 1. Models of TonB-dependent transport in Gram-negative bacteria. Various
mechanisms of TonB-dependent transport in pathogenic microorganism are shown and
distinguished by color. The model of siderophore-mediated iron uptake is shown in
yellow. The model of lactoferrin (Lf)- and transferrin (Tf)-mediated iron acquisition is
shown in blue. The third system, shown in red, illustrates the mechanisms of heme-iron
uptake from hemoglobin (Hb) and haptoglobin (Hg) in Neisseria. Components of each
system are labeled: integral, outer membrane transporters in the outer membrane,
periplasmic binding proteins (PBP) in the periplasm, cytoplasmic membrane-associated
TonB/ExbB/ExbD complexes and ABC transporters.
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Figure 2. Characterized TonB-dependent transporters. Figure modified from K. D.
Krewulak and H. J. Vogel review (104). TonB-dependent transporters are represented as
ribbon diagrams: (1) E. coli BtuB (40), vitamin B12 transporter; (2) E. coli FecA (61),
ferric-citrate transporter; (3) E. coli FepA (28), ferric-enterobactin transporter; (4) E. coli
FhuA (62, 119), ferrichrome transporter; (5) P. aeruginosa FptA (43), pyochelin
transporter; and (6) P. aeruginosa FpvA (42), pyoverdine transporter. The characteristic
β-barrel domains, shown in blue, are each comprised of 22 β-stand transmembranespanning domains. The globular plug domains, shown in green, are folded up within the
β-barrel domain and occlude the pore.
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Figure 3. Neisseria TbpA topology model. This TbpA two-dimensional, topology
model was generated based on the structures of characterized E. coli TonB-dependent
siderophore transporters. From these structures, it is predicted that TbpA has two distinct
domains. The C-terminal β-barrel domain is shown in blue with 22 putative β-strand
transmembrane domains and eleven putative extracellular loops. The loops labeled in
blue indicate those that are known to be surface exposed (242). The red circles indicate
cysteine residues that likely participate in disulfide bond formation within the loops. The
N-terminal plug domain is shown in the periplasm, but is predicted to fold up within the
β-barrel to occlude the pore.
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CHAPTER 2 – MATERIALS AND METHODS
I. Bacterial Growth Conditions
Gonococcal strains were routinely propagated on GC medium base (Difco) with
Kellogg’s supplement 1 (96) and 12 μM Fe(NO3)3. For selection of gonococcal
transformants, gonococci were grown on GC agar plates supplemented with 100 μg/ml of
streptomycin (Sigma) for selection of lbpB::Ω, tonB::Ω, and pilQ::Ω mutations, 1 μg/ml
of chloramphenicol (Sigma) for selection of the tbpA::mTn3cat mutation, or 1 μg/ml of
erythromycin (Sigma) for selection of dsbC::ermC, traC::ermC, traH::ermC, and
traN::ermC mutations. For growth under iron-stressed conditions, which promotes
maximal expression of the transferrin binding proteins, gonococci were cultured from GC
agar plates into acid-washed glassware containing liquid, chelexed defined medium
(CDM) (144, 234). All gonococcal strains were cultivated at 37oC with 5% CO2. CDM
agarose plates were supplemented with 5%, 10%, 30%, 50%, or 80% iron-saturated
human transferrin (Sigma) as needed to assess the ability of gonococcal mutants to utilize
transferrin-bound iron (48). Gonococcal growth on CDM-transferrin plates was
monitored over 24 – 72 hours. Plasmids were routinely propagated in TOP10
(Invitrogen) or NovaBlue (Novagen) E. coli strains, grown at 37oC in LB media (10, 11)
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supplemented with 50 μg/ml of kanamycin (Sigma) or 100 μg/ml of ampicillin (Sigma).
Strains and plasmids described in this study are listed in Tables 2 and 3, respectively.

II. Neisseria gonorrhoeae Mutagenesis
A. Mutagenic oligonucleotide design
According to the method of Horton et al. (84), both gene specific and mutagenic
oligonucleotides were designed to overlap for gene splicing by overlap extension or gene
SOEing (Figure 4). Oligonucleotides were designed to carry out site-directed alanine
substitution mutagenesis of the tbpA plug-encoding domain and to incorporate unique
restriction sites for subsequent screening of gonococcal mutants. Mutagenic and gene
specific oligonucleotides were synthesized by Integrated DNA Technologies and are
listed in Tables 4 and 5, respectively.
B. Site-directed alanine substitution mutagenesis
Site-specific, alanine substitution mutagenesis of the tbpA plug-encoding domain
was performed using gene splicing by overlap extension shown in Figure 4 (84). Briefly,
in the primary PCR step, two reactions were performed to amplify the upstream and
downstream portions of the tbpA plug-encoding domain. Mutagenic and non-mutagenic,
gene specific oligonucleotides used in these reactions are listed in Table 4 and 5,
respectively. Each mutagenic oligonucleotide was designed to encode one or more
alanines as well as novel restriction sites for subsequent screening of gonococcal mutants.
The template used in these reactions was pUNCH411, which contains the entire coding
region of tbpA (47) (Table 3). For the secondary PCR, the two primary amplification
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products were used as template with non-mutagenic oligonucleotides (Table 5). In this
reaction, the alanine-encoding sequences annealed to one another and served to prime the
next polymerization step. The final PCR product was gel extracted (Qiagen), purified,
and cloned into pCR2.1 TOPO (Invitrogen). The plasmids containing the various
mutagenized tbpA fragments (pVCU250 – pVCU260) are listed in Table 3. Mutagenized
tbpA fragments were sequenced by the Nucleic Acids Research Facility at Virginia
Commonwealth University to verify the expected sequences.
C. E. coli transformation
PCR products generated by gene splicing by overlap extension (84) were inserted
into pCR2.1 TOPO (Invitrogen) (Table 3) and these constructs were used to transform
TOP10 (Invitrogen) E. coli (Table 2). These plasmids were propagated in E. coli then
isolated and purified using the Qiagen QIAprep Spin Miniprep Kit. These plasmid
constructs were sequenced to ensure proper gene sequence as well as the preservation of
the reading frame by the Nucleic Acids Research Facilities of Virginia Commonwealth
University.
For subcloning into pHSS6-GCU (60) (Table 3), pCR2.1 TOPO constructs were
digested with EcoRI (New England BioLabs) to remove the PCR product inserts. EcoRIlinearized pHSS6-GCU and inserts were purified (Qiagen) and pHSS6-GCU plasmids
were treated with shrimp alkaline phosphatase (SAP) (Roche Molecular Biosciences).
Linearized pHSS6-GCU and inserts were incubated with DNA ligase (Invitrogen) for one
hour at 25oC. Chemically competent TOP10 E. coli cells (Invitrogen) were transformed
with pHSS6-GCU constructs (pVCU251 – pVCU261), containing tbpA encoding alanine
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substitutions (Table 3). The resulting E. coli strains (RIC250 – RIC261) are listed in
Table 2.
D. N. gonorrhoeae spot transformation
Alanine-encoding tbpA fragments were subcloned into pHSS6-GCU (60) (Table
3) to incorporate the gonococcal uptake (GCU) sequence necessary for transformation.
Resulting plasmids (pVCU251 – pVCU261) were then used to transform gonococcal
strains FA19 (TbpB+) and FA6905 (TbpB−) (Table 2). Congression, described below,
was used to provide a selectable marker for the transformation event. Chromosomal
DNA from MCV601 (14) (Table 2), which contains an Ω cassette inserted into lbpB
(encoding lactoferrin binding protein B), was used in conjunction with the linearized
pHSS6-GCU contructs. These donor DNAs were combined and used to transform
piliated FA19 (TbpB+) or FA6905 (TbpB−). Approximately 10 CFU were spotted on a
GC agar plate and both donor DNAs were applied on top of the piliated gonococci.
Transformation mixtures were incubated on non-selective media for 24 hours at 37oC
with 5% CO2. Transformants were then selected on 100 μg/ml of streptomycin,
resistance to which was encoded by the Ω cassette. A subsequent PCR and restriction
digest identified streptomycin-resistant transformants with the introduced restriction sites.
This process yielded strains MCV250 – MCV261 (Table 2), which contained single,
double, or triple alanine-encoding mutations within the tbpA plug-encoding domain.
As previously described (57), when two mutations were combined, linearized
plasmids containing each independent mutation were simultaneously added to piliated
gonococci along with the streptomycin-resistant MCV601 chromosomal DNA. These
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combined mutants (MCV262 – MCV266) contain mutations in both tbpA and tbpB and
are listed in Table 2. Gonococcal tbpA and tbpB were sequenced by the Nucleic Acids
Research Facility at Virginia Commonwealth University to verify mutations in both
genes.
E. N. gonorrhoeae liquid transformation
For revertant analysis, various mutations were made in FA19, MCV511 (L3HA),
and MCV267 (L3HA revertant) backgrounds. Plasmids pUNCH290 (pilQ::Ω), pHH17
(dsbC::ermC), pKS83 (traC::ermC), pJD1175 (traH::ermC), and pKS72 (traN::ermC)
(Table 3) were used to generate PilQ and T4SS deletion mutants. pUNCH290 and
pHH17 were linearized to select for a double crossover insertion of the Ω cassette and
ermC into pilQ and dsbC, respectively. pSK83, pJD1175, and pKS72 were not linearized
to select for a single crossover insertion of ermC into traC, traH, and traN, respectively.
Gonococcal strains, suspended in GCB/MgCl2 media, were mixed with the plasmid
DNAs and allowed to incubate for 30 minutes at 37°C with 5% CO2. Following
incubation, fresh GCB/MgCl2 media was added and gonococcal-plasmid DNA mixture
was incubated at 37°C with 5% CO2 for five hours. After five hour incubation, strains
were plated on selective media (100 μg/ml streptomycin for Ω insertion and 1 μg/ml
erythromycin for ermC insertions) and resulting transformants were selected (MCV270 –
MCV286) and are listed in Table 2.

III. Western Blot Analysis and Solid-Phase HA Binding
A. SDS-PAGE and protein transfer
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Gonococcal strains were grown in liquid CDM to induce iron stress (234). After
four hours of growth, aliquots were removed and standardized to culture cell density.
Cells were pelleted and lysed with Laemmli solubilizing buffer (107) and stored at
−20oC. Before use, 5% β-mercaptoethanol (Fisher Scientific) was added to the whole
cell lysates; lysates were heated at 95oC for three minutes, and then drawn through a 28gauge syringe (Beckton Dickinson) to decrease viscosity of samples. Whole cell lysates
were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) on 7.5%, 12%, or 15% gels. Proteins were subsequently transferred to
nitrocellulose membranes (Schleicher and Schuell) in 20 mM Tris base, 150 mM glycine,
and 20% methanol (218) within a submerged transfer apparatus (Bio-Rad) at 28 mAmp
for 18 – 20 hours. Prior to immunoblotting, nitrocellulose membranes were incubated in
Ponceau S (Fisher) stain (0.1% w/v Ponceau S and 5% acetic acid) to ensure equal
protein loading.
B. TbpA, TbpB, and TonB detection
For detection of TbpA, TbpB, and TonB, membranes were blocked with 5%
bovine serum albumin (BSA) (Roche) in high salt Tris-buffered saline (HS TBS) plus
0.05% Tween-20 (Sigma). TbpA blots were then probed with a 1:1,000 dilution of
primary anti-TbpA polyclonal antibodies (50), while TbpB and TonB blots were probed
with a 1:5,000 dilution of primary anti-TbpB (215) or anti-TonB (97) polyclonal
antibodies. Blots were then washed with HS TBS plus 0.05% Tween-20, and probed
with a 1:10,000 dilution of secondary goat anti-rabbit AP (alkaline phosphatase) antibody
(Bio-Rad). Western blots were developed using NBT/BCIP developing system (Sigma).
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C. Hemagglutinin (HA) epitope detection
For detection of the hemagglutinin (HA) epitope, membranes were blocked in 5%
Western blocking reagent (Roche) in low salt Tris-buffered saline (LS TBS). HA blots
were then probed with a 1:500 dilution of anti-HA horseradish peroxidase high-affinity
monoclonal antibody (HRP-HA) (Roche) and subsequently washed with LS TBS. Blots
were developed using Perkin Elmer Chemiluminescence (ECL) Plus and reactive bands
were detected by exposure to film (Kodak).
D. Solid-phase anti-HA binding assay
Gonococcal strains were grown for four hours in liquid CDM to induce iron stress
(234). Aliquots were standardized to culture cell density and then spotted onto
nitrocellulose membranes (Schleicher and Schuell). Membranes were dried and then
blocked with 5% Western blocking reagent (Roche) in LS TBS. Dot blots were then
probed with a 1:500 dilution of anti-HA horseradish peroxidase-conjugated monoclonal
antibody (HRP-HA) (Roche) and subsequently washed with LS TBS. Dot blots were
developed using Opti-4CN (BioRad).

IV. Surface Exposure and Transferrin Binding
A. Solid-phase transferrin binding assay
Gonococcal strains were grown in liquid CDM for four hours to induce iron stress
(234). Aliquots were standardized to culture cell density and then spotted onto
nitrocellulose membranes (Schleicher and Schuell). Membranes were dried and blocked
with 5% skim milk (BioRad) in LS TBS. To assess solid-phase transferrin binding by
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gonococcal cells, membranes were incubated with a 1:1,000 dilution of horseradish
peroxidase-conjugated transferrin (HRP-Tf) (Jackson ImmunoResearch), washed with LS
TBS, and then developed with Opti-4CN (BioRad).
B. Solid-phase transferrin discrimination assay
Gonococcal strains were grown in liquid CDM for four hours to induce iron stress
(234). Aliquots were standardized to culture cell density and then spotted onto
nitrocellulose membranes (Schleicher and Schuell). Membranes were dried and then
blocked with 5% skim milk in LS TBS. Ligand discrimination was determined by
probing membranes with a mixture of unlabeled competitor (100% saturated human
transferrin or apo-transferrin) (Sigma) and HRP-Tf. Two-fold serial dilutions of
unlabeled competitor, ranging from 0.05 – 6 μM, were mixed with 0.33 μg/ml of HRPTf. Following incubation with labeled and unlabeled transferrin, dot blots were washed
with LS TBS and developed with Opti-4CN (BioRad).

V. Quantitative Transferrin Binding
A. Iodination of human transferrin
Approximately 200 μl of 100% saturated human transferrin (Calbiochem) was
mixed with 10 μl (1 mCi) of Na125I (GE Biosciences) in an Iodogen-coated tube (Pierce).
The iodination reaction was carried out for 15 minutes at room temperature. The mixture
was added to 200 μl of column loading dye (10% glycerol, 0.1% bromophenol blue,
0.3% blue dextran) and transferred to a dextran desalting column (Pierce). This column
was equilibrated with 50 ml of PBS before the addition of 125I-transferrin. The column

separated free

125

I from the

125

46
I-transferrin, which was collected in the flow through. The

concentration of 125I-transferrin was then determined by BCA assay (Pierce).
B. Equilibrium-phase transferrin binding assay
Equilibrium-phase transferrin binding assays were performed as previously
described (50) to determine TbpA or TbpB transferrin binding affinity and capacity.
Briefly, human transferrin (Calbiochem) was iodinated with 125I (GE Biosciences) and
specific activity was determined by gamma counting. Both iodinated transferrin and
unlabeled competitor transferrin were quantitated using a BCA assay (Pierce).
Gonococcal strains were grown in liquid CDM for three hours to induce iron stress (234).
Following growth, 100 μl of each culture was added to a Millipore Multiscreen microtiter
plate and incubated with various concentrations of 125I-labeled transferrin (0 – 100 nM) to
determine total transferrin binding. In addition, cultures were incubated with 125Itransferrin and excess unlabeled transferrin to determine non-specific transferrin binding.
Specific transferrin binding was determined by subtracting non-specific binding from
total binding. Specific transferrin bound (ng Tf) was standardized to micrograms of total
cellular protein (μg TCP) in 100 μl of culture, as determined by BCA assays (Pierce).
Each graph represents averages and standard deviations from at least three separate
assays, each of which was performed in quadruplicate. Kd (affinity) and capacity values
as well as standard errors were calculated using Grafit software (Erithacus Software).

VI. Transferrin-Iron Internalization
A. Iron-saturation of human transferrin
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Apo-human transferrin (Calbiochem) was resuspended in ferration buffer, pH 8.4
(100 mM Tris, 150 mM NaCl, 20 mM NaHCO3) to a concentration of 10 mg/ml. Iron
solution, pH 8.6 (100 mM Na3C6H5O7, 100 mM NaHCO3, 5 mM FeCl3 or 55FeCl3) was
added to achieve the desired saturation level and saturation was allowed to proceed for
one hour at room temperature. Ferrated transferrin was then dialyzed overnight at 4oC in
a 400-fold volume of dialysis buffer, pH 7.4 (400 mM Tris, 150 mM NaCl, 20 mM
NaHCO3). The buffer was then replaced with fresh dialysis buffer and dialysis was
allowed to proceed for an additional four hours at room temperature. Dialysis of 55Fetransferrin was performed similarly against a 1000-fold volume of dialysis buffer for four
hours at room temperature without buffer exchange.
To verify the iron saturation level of the transferrin, ferrozine assays were
performed. A standard curve of iron concentrations was created in the range of 0.05 –1.0
μg/ml and the transferrin-iron saturation was determined from this curve. Acid reagent
[0.01 M ferrozine (3-(2-puridyl)-5, 6 bis (4-phenlysulphonic acid) 1, 2, 3 triamine) in
approximately 50% hydrochloric acid] was added to each sample and then allowed to
boil for ten minutes. Buffer reagent (5.2 M ammonium acetate in 35% acetic acid) was
then added to each sample after cooling to room temperature. Absorbance readings were
taken at 562 nm. The concentration of transferrin was determined using a BCA assay
(Pierce) and the percent saturation was calculated based on the ability of transferrin to
bind two atoms of iron.
B. Transferrin-iron uptake assay
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Transferrin-iron uptake assays were performed as previously described (4, 12,
46). Briefly, human transferrin (Calbiochem) was ferrated with 55FeCl3 (Perkin Elmer) to
achieve 20% iron saturation. Gonococcal strains were grown in liquid CDM for three
hours to induce iron stress (234). Following growth, 100 μl of each culture was added in
quadruplicate sets to two Millipore multiscreen microtiter plates. To one set of cultures
40 μM potassium cyanide (KCN) (Sigma) was added to determine non-specific iron
binding. Approximately 0.9 μM 20% iron-saturated transferrin was added to each well
and incubated at 37oC with 5% CO2 for 30 minutes to allow for iron internalization.
Following incubation, plates were filtered to remove transferrin, washed with citrate
buffer (100 mM Na3C6H5O7, 1.0 mM MgCl2, 0.25 mM CaCl2), dried, and counted using
a Beckman LS6500 beta scintillation counter. All counts were averaged and non-specific
counts (KCN plate) were subtracted from total counts to obtain specific iron
internalization. Specific iron uptake, reported in picomoles, for each strain was
standardized to micrograms of total cellular protein (TCP) in 100 μl of culture, as
determined by BCA assay (Pierce). Each graph represents the means and standard
deviations from at least six separate assays, each of which was performed in
quadruplicate.
C. Modified transferrin-iron uptake assay with desferal
Modified transferrin-iron uptake assays were performed similarly to what was
previously described (4, 12, 46) with some modifications. Briefly, human transferrin
(Calbiochem) was ferrated with 55FeCl3 (Perkin Elmer) to achieve 20% iron saturation.
Gonococcal strains were grown in liquid CDM for three hours to induce iron stress (234).
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Following growth, 100 μl of each culture was added in quadruplicate sets to two
Millipore multiscreen microtiter plates. To one set of cultures 40 μM potassium cyanide
(KCN) (Sigma) was added to determine non-specific iron binding. Approximately 0.9
μM 20% iron-saturated transferrin and 50 mM desferal (Sigma) were added to wells for 0
– 40 minutes of incubation at room temperature. Following incubation, plates were
filtered to remove transferrin and desferal, washed with citrate buffer (100 mM
Na3C6H5O7, 1.0 mM MgCl2, 0.25 mM CaCl2), dried, and counted using a Beckman
LS6500 beta scintillation counter. Counts were averaged at each time point and nonspecific counts (KCN plate) were subtracted from total counts to obtain specific iron
internalization. Specific iron uptake, reported in picomoles, for each strain was
standardized to micrograms of total cellular protein (TCP) in 100 μl of culture, as
determined by BCA assay (Pierce). Each graph represents averages and standard
deviations from three separate experiments, each of which was performed in
quadruplicate.

VII. Recombinant Protein Expression and Purification
A. Construction of S-tag and His-tag protein expression plasmids
For S-tagged protein constructs, tbpA plug, fetA plug, fbpA, and tonB expression
plasmids were constructed by PCR amplification of tbpA, fetA, fbpA, and tonB from
gonococcal strain FA19 chromosomal DNA. Primers were designed to amplify these
genes and engineered with BglII and XhoI restriction sites at the 5’ and 3’ ends,
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respectively (Table 4). These restriction sites allowed for directional cloning into the
pET-29b(+) expression vector (Novagen) (Table 3).
For His-tagged protein constructs, tbpA plug, fbpA, and exbB expression plasmids
were constructed by PCR amplification of tbpA, fbpA, and exbB from FA19 chromosomal
DNA. Primers were designed to amplify these genes and engineered with NdeI and XhoI
restriction sites at the 5’ and 3’ ends, respectively (Table 4). These restriction sites
allowed for directional cloning into the pET-22b(+) expression vector (Novagen) (Table
3).
The resultant PCR products were ligated into pCR2.1 TOPO (Invitrogen)
(pVCU262 – pVCU270) and propagated in E. coli TOP10 cells (Invitrogen) (RIC262 –
RIC274) (Table 2). Plasmids were then sequenced by the Nucleic Acids Research
Facility at Virginia Commonwealth University to verify the expected sequences.
Plasmids were digested with BglII or NdeI and XhoI enzymes (New England BioLabs) to
excise inserts. Following digestion, the gene products were isolated and purified using
the Qiagen QIAprep Spin Miniprep Kit and ligated into linearized pET-29b(+) or pET22b(+) expression vectors (Novagen) (pVCU263 – pVCU271) (Table 3). The resultant
plasmids were propagated in E. coli NovaBlue cells (Novagen) (RIC263 – RIC275)
(Table 2). These plasmid constructs contained the gene of interest under the control of a
T7 promoter, as well as a 5’ region encoding an S-tag or a 3’ region encoding a 6x Histag for purification. For expression of these gene products, the E. coli expression strain
BL21(DE3) (Novagen), which expressed T7 polymerase under the control of the lac
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promoter, was transformed with these constructs. These strains, RIC264 – RIC276, are
described in Table 2.
B. Recombinant protein expression
For expression of recombinant proteins, starter cultures of BL21(DE3) expression
strains were grown for approximately six hours at 37oC, shaking at 225 rpm, in LB media
containing 50 μg/ml of kanamycin (pET29b(+)) or 100 μg/ml of ampicillin (pET22b(+)).
Following growth, cultures were stored at 4oC until use in large-scale growth and
induction. Prior to large-scale induction, starter cultures were subject to centrifugation at
5000 x g for ten minutes and the supernatants were removed. Fresh LB media with 50
μg/ml of kanamycin or 100 μg/ml of ampicillin was added to resuspend the bacterial cell
pellets. The starter cultures were then used to inoculate 1L of LB broth containing 50
μg/ml of kanamycin or 100 μg/ml of ampicillin. The cultures were incubated at 37oC
with shaking at 225 rpm until the OD600 reached 0.4 – 0.8. After cultures reached the
optimal cell density, 1 mM IPTG (isopropyl-B-D-thiogalactopyranoside) (Sigma) was
added to induce protein expression. Induction was allowed to proceed for four hours at
37oC with shaking at 225 rpm. Following four hour protein induction, cultures were
subject to centrifugation at 10,000 x g for ten minutes and then supernatants were
removed. Pellets were dried and stored at −20oC overnight.
C. Recombinant protein purification
For purification of S-tagged recombinant proteins, bacterial cell pellets were
thawed and resuspended in BugBuster reagent (Novagen) according to manufacturer’s
instructions. After cells were completely resuspended, benzonase nuclease (Novagen),
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protease inhibitors (Sigma), and lysozyme (Sigma) were added to the cultures and
incubated for 30 minutes at room temperature. Solubilized preparations were then
subject to centrifugation at 16,000 x g at 4oC for 30 minutes to remove insoluble cellular
debris. Cleared lysates were then transferred to sterile tubes and incubated with S-protein
agarose (Novagen) at room temperature for 30 minutes on an orbital shaker. Samples
were then subjected to centrifugation at 500 x g for ten minutes and supernatants were
carefully removed. S-protein agarose resin was then resuspended in 5 ml of 1x
Bind/Wash Buffer (200 mM Tris-HCl pH 7.5, 1.5 M NaCl, and 1% Triton X-100), gently
mixed, and pelleted at 500 x g three times. Washed resin was then resuspended in 3 M
MgCl2 elution buffer at a volume 1.5 times that of the settled resin and incubated for ten
minutes at room temperature. Resin was then applied to a disposable column and Stagged recombinant proteins were eluted.
For purification of His-tagged recombinant proteins, Qiagen protocols were
followed. Bacterial cell pellets were thawed on ice and resuspended in lysis buffer (50
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, final pH 8.0), benzonase nuclease
(Novagen), protease inhibitors (Sigma) and lysozyme (Sigma) mixture. Resuspended
cells were incubated for 30 minutes on ice and then subjected to sonication. Cellular
debris was removed by centrifugation at 16,000 x g for 30 minutes at 4oC. Cleared
lysates were transferred to sterile tubes and incubated with 50% Ni-NTA slurry (Qiagen)
at 4oC for one hour. Lysate-Ni-NTA mixtures were then added to disposable columns
and flow-through fractions were collected. Resin was washed twice with wash buffer (50
mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, final pH 8.0) and washed fractions
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were collected. His-tagged recombinant proteins were eluted from the column with
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, final pH 8.0).
Purified proteins were dialyzed against a 1000-fold excess PBS.
D. SDS-PAGE, protein transfer, and detection
Protein fractions were diluted with Laemmli solubilizing buffer (107) and stored
at −20oC. Before use, 5% β-mercaptoethanol (Fisher Scientific) was added to the
samples and they were heated at 95oC for three minutes. After boiling, samples were
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on
a 15% gel. Proteins were subsequently transferred to nitrocellulose membranes
(Schleicher and Schuell) in 20 mM Tris base, 150 mM glycine, and 20% methanol (218)
within a submerged transfer apparatus (Bio-Rad) at 28 mAmp for 18-20 hours.
For detection of S-tagged and His-tagged recombinant proteins, membranes were
blocked with 5% skim milk in low salt Tris-buffered saline (LS TBS). Blots were then
probed with a 1:5,000 dilution of anti-S-tag monoclonal antibodies (Novagen) or a
1:1,000 dilution of anti-His-tag monoclonal antibodies (Calbiochem) , washed with LS
TBS, and then probed with a 1:10,000 (S-tag) or 1:5,000 (His-tag) dilution of a secondary
goat anti-mouse IgG AP (BioRad). Blots were developed using NBT/BCIP developing
system (Sigma).
E. Coomassie blue protein staining
SDS-PAGE gels were stained with Coomassie blue (0.25% Coomassie R-250,
50% methanol, 10% glacial acetic acid) following electrophoresis. Gels were incubated
with Coomassie blue stain overnight at room temperature and then destained in 20%
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methanol and 5% glacial acetic acid at room temperature until background staining was
minimized. Prior to drying, gels were incubated in gel drying buffer (40% methanol,
10% glycerol, and 7.5% glacial acetic acid) for one hour.

VIII. Recombinant Protein-Iron Binding Assay
Recombinant iron binding assays were performed in Millipore Multiscreen
microtiter plates. To assess total iron binding, 50 μg of each S-tagged or His-tagged
recombinant protein was incubated with 5% BSA in PBS, NaHCO3, 55FeCl3, and NiNTA resin. Phosphate and carbonate served as coordinating anions for iron binding in
this assay. To assess non-specific iron binding by recombinant proteins, proteins were
treated the same as above, but incubated in the presence of 1000-fold excess cold FeCl3
or Fe(NO3)3 competitor. As an additional control for non-specific binding to the Ni-NTA
resin, 5% BSA, NaHCO3, 55FeCl3, and Ni-NTA resin were incubated in the absence of
recombinant protein. Microtiter plates were incubated at room temperature for 30
minutes on a platform shaker at 200 rpm. Following incubation, wells were filtered and
washed with citrate buffer (100 mM Na3C6H5O7, 1.0 mM MgCl2, 0.25 mM CaCl2). Once
dried, filters were removed and counted using a Beckman LS6500 beta scintillation
counter. Counts were averaged and specific iron binding was determined by subtracting
both sets of non-specific counts from the total iron binding counts. Each graph represents
averages and standard deviations from three separate experiments, each performed in
quadruplicate sets.

55
IX. Statistical Analysis
Statistical significance of equilibrium-phase transferrin binding data, modified
and standard transferrin-iron uptake data, and iron binding data was determined using a
two-tailed equal variance Student’s t test. Statistical significance is noted when P ≤ 0.05
and specific values are shown with each data set.
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Figure 4. Schematic representation of mutagenesis by gene SOEing. Non-mutagenic
primers 1 and 4 were used to amplify the upstream (black) and downstream (gray)
regions of the plug-encoding region of tbpA in primary PCR reactions. Mutagenic
primers 2 and 3 were also used to introduce sequences encoding altered amino acid
residues and novel restriction sites (red) in the primary PCR reactions. The primary PCR
products were amplified with non-mutagenic primers 1 and 4 in the secondary PCR. The
primary PCR products served as template in this reaction and overlapping sequences
served to prime the secondary PCR.
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Table 2: Escherichia coli and Neisseria gonorrhoeae strains

Strain

Phenotype (genotype)

Reference

Invitrogen

BL21(DE3)
RIC250

F− mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15
ΔlacX74 recA1 deoR araD139 Δ(ara-leu)7697 alU
galK rpsL(StrR) endA1 nupG
endA1 hsdR17 (rK12– mK12+) supE44 thi-1 recA1
gyrA96 relA1 lac F′[proA+B+ lacIqZΔM15::Tn10]
(TetR)
F– ompT hsdSB (rB– mB–) gal dcm (DE3)
TOP10 transformed with pVCU250 (tbpA E118A)

RIC251

TOP10 transformed with pVCU251 (tbpA E118A)

RIC252

TOP10 transformed with pVCU252 (tbpA E120A)

RIC253

TOP10 transformed with pVCU253 (tbpA E120A)

RIC254

TOP10 transformed with pVCU254 (tbpA Y121A)

RIC255

TOP10 transformed with pVCU255 (tbpA Y121A)

RIC256

TOP10 transformed with pVCU256 (tbpA E122A)

RIC257

TOP10 transformed with pVCU257 (tbpA E122A)

RIC258

TOP10 transformed with pVCU258 (tbpA
EY120AA)
TOP10 transformed with pVCU259 (tbpA
EY120AA)
TOP10 transformed with pVCU260 (tbpA
EYE120AAA)
TOP10 transformed with pVCU261 (tbpA
EYE120AAA)
TOP10 transformed with pVCU262 (tbpA plug)
NovaBlue transformed with pVCU263 (tbpA plug)
BL21(DE3) transformed with pVCU263 (tbpA
plug)

E. coli
TOP10
NovaBlue

RIC259
RIC260
RIC261
RIC262
RIC263
RIC264

Novagen
Novagen
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
This study
This study
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RIC265
RIC266
RIC267
RIC268
RIC269
RIC270
RIC271
RIC272
RIC273
RIC274
RIC275
RIC276
RIC277
RIC278
RIC279

TOP10 transformed with pVCU264 (tbpA plug)
NovaBlue transformed with pVCU265 (tbpA plug)
BL21(DE3) transformed with pVCU265 (tbpA
plug)
TOP10 transformed with pVCU266 (fetA plug)
NovaBlue transformed with pVCU267 (fetA plug)
BL21(DE3) transformed with pVCU267 (fetA plug)
TOP10 transformed with pVCU268 (fbpA)
NovaBlue transformed with pVCU269 (fbpA)
BL21(DE3) transformed with pVCU269 (fbpA)
TOP10 transformed with pVCU270 (tonB)
NovaBlue transformed with pVCU271 (tonB)
BL21(DE3) transformed with pVCU271 (tonB)
TOP10 transformed with pVCU272 (tbpA plug
EYE120AAA)
NovaBlue transformed with pVCU273 (tbpA plug
EYE120AAA)
BL21(DE3) transformed with pVCU273 (tbpA plug
EYE120AAA)

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

N. gonorrhoeae
FA19
FA6905
FA6747
FA6815
MCV601
MCV250

TbpA+, TbpB+
TbpA+, TbpB− (ΔtbpB)
TbpA− (tbpA::mTn3cat), TbpB+
TbpA−, TbpB− (tbpB::Ω)
FA19 derivative, LbpB− (lbpB::Ω)
TbpA E118A, TbpB+

MCV251

TbpA E118A, TbpB− (ΔtbpB)

MCV252

TbpA E120A, TbpB+

MCV253

TbpA E120A, TbpB− (ΔtbpB)

MCV254

TbpA Y121A, TbpB+

MCV255

TbpA Y121A, TbpB− (ΔtbpB)

MCV256

TbpA E122A, TbpB+

MCV257

TbpA E122A, TbpB− (ΔtbpB)

(138)
(50)
(48)
(4)
(14)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
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MCV258

TbpA EY120AA, TbpB+

MCV259

TbpA EY120AA, TbpB− (ΔtbpB)

MCV260

TbpA EYE120AAA, TbpB+

MCV261

TbpA EYE120AAA, TbpB− (ΔtbpB)

MCV845

TbpA+, TbpB CC481AA

MCV846

TbpA− (tbpA::mTn3cat), TbpB CC481AA

MCV812
MCV816
MCV824
MCV515
MCV516
MCV519
MCV520
MCV527
MCV528
MCV262

TbpA+, TbpB HA3175 (tbpB∇HA)
TbpA+, TbpB HA5327 (tbpB∇HA)
TbpA+, TbpB HA9660 (tbpB∇HA)
TbpA L9HA750 (tbpA∇HA), TbpB+
TbpA L9HA750 (tbpA∇HA), TbpB− (ΔtbpB)
TbpA L11HA843 (tbpA∇HA), TbpB+
TbpA L11HA843 (tbpA∇HA), TbpB− (ΔtbpB)
TbpA L2HA229 (tbpA∇HA), TbpB+
TbpA L2HA229 (tbpA∇HA), TbpB− (ΔtbpB)
TbpA EYE120AAA, TbpB CC481AA

MCV263

TbpA EYE120AAA, TbpB HA3175

MCV264

TbpA EYE120AAA, TbpB HA5327

MCV265

TbpA EYE120AAA, TbpB HA9660

MCV266

TbpA L9HA750, TbpB CC481AA

MCV828
MCV830
MCV834

TbpA L9HA750, TbpB HA3175
TbpA L9HA750, TbpB HA5327
TbpA L9HA750, TbpB HA9660

This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(56)
This study
(56)
(57)
(57)
(57)
(243)
(243)
(243)
(243)
(243)
(243)
This study
(DeRocco
unpublished)
This study
(DeRocco
unpublished)
This study
(DeRocco
unpublished)
This study
(DeRocco
unpublished)
This study
(DeRocco
unpublished)
(57)
(57)
(57)

Pseudo-revertant gonococcal studies
MCV511

TbpA L3HA343, TbpB+

(243)
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MCV512
MCV523
MCV524
MCV267

TbpA L3HA343, TbpB− (ΔtbpB)
TbpA β16HA713, TbpB+
TbpA β16HA713, TbpB− (ΔtbpB)
TbpA L3HA343, TbpB+ revertant

MCV268

TbpA β16HA713, TbpB+ revertant

(243)
(243)
(243)
This study
(Yost-Daljev
unpublished)
This study
(Yost-Daljev
unpublished)

FA19 derived strains
MCV269
MCV270
MCV271
MCV272
MCV273
MCV274
MCV904
MCV906

TbpA+, TbpB+, TonB− (tonB::Ω)
TbpA+, TbpB+, PilQ− (pilQ::Ω)
TbpA+, TbpB+, DsbC− (dsbC::ermC)
TbpA+, TbpB+, TraC− (traC::ermC)
TbpA+, TbpB+, TraH− (traH::ermC)
TbpA+, TbpB+, TraN− (traN::ermC)
TbpA+, TbpB+, FbpA− (fbpA::ermClacIP) −RBS
TbpA+, TbpB+, FbpA− (fbpA::ermClacIP)

This study
This study
This study
This study
This study
This study
(211)
(211)

MCV511 (L3HA) derived strains
MCV275
MCV276
MCV277
MCV278
MCV279

TbpA L3HA343, TbpB+, PilQ− (pilQ::Ω)
TbpA L3HA343, TbpB+, DsbC− (dsbC::ermC)
TbpA L3HA343, TbpB+, TraC− (traC::ermC)
TbpA L3HA343, TbpB+, TraH− (traH::ermC)
TbpA L3HA343, TbpB+, TraN− (traN::ermC)

This study
This study
This study
This study
This study

MCV267 (pseudo-revertant) derived strains
MCV280
MCV281
MCV282
MCV283
MCV284
MCV285
MCV286
MCV287
MCV288

TbpA L3HA343, TbpA− (tbpA::mTn3cat), TbpB+
TbpA L3HA343, TonB− (tonB::Ω)
TbpA L3HA343, TbpB+, PilQ− (pilQ::Ω)
TbpA L3HA343, TbpB+, DsbC− (dsbC::ermC)
TbpA L3HA343, TbpB+, TraC− (traC::ermC)
TbpA L3HA343, TbpB+, TraH− (traH::ermC)
TbpA L3HA343, TbpB+, TraN− (traN::ermC)
TbpA L3HA343, TbpB+, FbpA− (fbpA::ermClacIP)
−RBS
TbpA L3HA343, TbpB+, FbpA− (fbpA::ermClacIP)

This study
This study
This study
This study
This study
This study
This study
This study
This study
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Table 3: Plasmids

Plasmid

Description

Reference

Constructs for generation of N. gonorrhoeae mutants
pCR2.1
TOPO
pHSS6-GCU
pUNCH411
pUNCH403
pVCU693
pUNCH290
pHH17
pKS83
pJD1175
pKS72
pVCU912
pVCU913
pVCU250
pVCU251
pVCU252
pVCU253
pVCU254
pVCU255
pVCU256
pVCU257
pVCU258
pVCU259
pVCU260

KanR AmpR

Invitrogen

Vector containing gonococcal uptake sequence (KanR)
pBS-SK(+) containing entire tbpA gene
Vector containing tbpA::mTn3cat
pCR2.1 TOPO containing tonB::Ω
Vector containing pilQ::Ω
pHSS6-GCU derivative containing dsbC::ermC

(60)
(47)
(48)
(74)
(37)
(Hamilton
unpublished)
(76)
(77)
(76)
(211)
(211)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)
This study
(160)

pHSS6-GCU derivative containing traC::ermC
pHSS6-GCU derivative containing traH::ermC
pHSS6-GCU derivative containing traN::ermC
pHSS6-GCU containing fbpA::ermClacIP (−RBS)
pHSS6-GCU containing fbpA::ermClacIP
pCR2.1 TOPO containing tbpA gene amplified with
oVCU334 and oVCU335; E118A, PvuI restriction site
pHSS6-GCU containing EcoRI fragment from
pVCU250
pCR2.1 TOPO containing tbpA gene amplified with
oVCU334 and oVCU335; E120A, NdeI restriction site
pHSS6-GCU containing EcoRI fragment from
pVCU252
pCR2.1 TOPO containing tbpA gene amplified with
oVCU334 and oVCU335; Y121A, HaeIII restriction site
pHSS6-GCU containing EcoRI fragment from
pVCU254
pCR2.1 TOPO containing tbpA gene amplified with
oVCU334 and oVCU335; E122A, HpyCH4V restriction
site
pHSS6-GCU containing EcoRI fragment from
pVCU256
pCR2.1 TOPO containing tbpA gene amplified with
oVCU334 and oVCU335; EY120AA, PstI restriction site
pHSS6-GCU containing EcoRI fragment from
pVCU258
pCR2.1 TOPO containing tbpA gene amplified with
oVCU334 and oVCU335; EYE120AAA, PstI and AluI

This study
(160)
This study
(160)
This study
(160)
This study
(160)
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pVCU834

restriction sites
pHSS6-GCU containing EcoRI fragment from
pVCU260
pCR2.1 TOPO containing tbpB encoding CC481AA

pCVU835

pHSS6-GCU containing tbpB encoding CC481AA

pVCU813

pCR2.1 TOPO containing tbpB encoding HA3175

pVCU814

pHSS6-GCU containing tbpB encoding HA3175

pVCU817

pCR2.1 TOPO containing tbpB encoding HA5327

pVCU818

pHSS6-GCU containing tbpB encoding HA5327

pVCU825

pCR2.1 TOPO containing tbpB encoding HA9660

pVCU826

pHSS6-GCU containing tbpB encoding HA9660

pVCU521

pCR2.1 TOPO containing tbpA encoding L9HA750

pVCU261

This study
(160)
This study
(56)
This study
(56)
This study
(57)
This study
(57)
This study
(57)
This study
(57)
This study
(57)
This study
(57)
This study
(243)

Constructs for expression of His-tag proteins
pET-22b(+)
pVCU911
pVCU914
pVCU262
pVCU263
pVCU272
pVCU273

AmpR
pET22b(+) containing fbpA from gonococcal strain
FA19
pET22b(+) containing exbB from gonococcal strain
FA19
pCR2.1 TOPO containing tbpA plug-encoding region
amplified with oVCU289 and oVCU290
pET-22b(+) containing NdeI and XhoI fragment from
pVCU262
pCR2.1 TOPO containing tbpA plug-encoding region
(EYE120AAA) amplified with oVCU289 and oVCU290
pET-22b(+) containing NdeI and XhoI fragment from
pVCU272

Novagen
(175)
This study
(Strange
unpublished)
This study
This study
This study
This study

Constructs for expression of S-tag proteins
pET-29b(+)
pVCU264

KanR
pCR2.1 TOPO containing tbpA plug-encoding region
amplified with oVCU375 and oVCU376

Novagen
This study
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pVCU265
pVCU266
pVCU267
pVCU268
pVCU269
pVCU270
pVCU271

pET-29b(+) containing BglII and XhoI fragment from
pVCU264
pCR2.1 TOPO containing fetA plug-encoding region
amplified with oVCU377 and oVCU378
pET-29b(+) containing BglII and XhoI fragment from
pVCU266
pCR2.1 TOPO containing fbpA gene amplified with
oVCU379 and oVCU380
pET-29b(+) containing BglII and XhoI fragment from
pVCU268
pCR2.1 TOPO containing tonB gene amplified with
oVCU381 and oVCU382
pET-29b(+) containing BglII and XhoI fragment from
pVCU270

This study
This study
This study
This study
This study
This study
This study
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Table 4. Mutagenic oligonucleotides

Primer

Oligonucleotide sequence (5’-3’)

Target

Alanine-encoding tbpA oligonucleotidesa
oVCU336
oVCU337
oVCU338
oVCU339
oVCU340
oVCU341
oVCU342
oVCU343
oVCU344
oVCU345
oVCU346

oVCU347

GGCGCAATCAATGCGATCGAGTATGAG
(PvuI)
CTCATACTCGATCGCATTGATTGCGCC
(PvuI)
ATCAATGAAATCGCATATGAGAACGTC
(NdeI)
GACGTTCTCATATGCGATTTCATTGAT
(NdeI)
AATGAAATCGAGGCCGAGAACGTCAAG
(HaeIII)
CTTGACGTTCTCGGCCTCGATTTCATT
(HaeIII)
GAAATCGAGTATGCAAACGTCAAGGCT
(HpyCH4V)
AGCCTTGACGTTTGCATACTCGATTTC
(HpyCH4V)
ATCAATGAAATCGCTGCAGAGAACGTCAAG
(PstI)

tbpA
E118A
tbpA
E118A
tbpA
E120A
tbpA
E120A
tbpA
Y121A
tbpA
Y121A
tbpA
E122A
tbpA
E122A
tbpA
E120A
Y121A
CTTGACGTTCTCTGCAGCGATTTCATTGAT
tbpA
(PstI)
E120A
Y121A
GCAATCAATGAAATCGCTGCAGCTAACGTCAAGGCTGTC tbpA
(PstI, AluI)
E120A
Y121A
E122A
GACAGCCTTGACGTTAGCTGCAGCGATTTCATTGATTGC tbpA
(PstI, AluI)
E120A
Y121A
E122A
Restriction site incorporating oligonucleotidesb

oVCU289

CATATGGAAAATGTGCAAGCCGGACAAGC
(NdeI)

tbpA
plug

oVCU290

CTCGAGCCTGCCTTCCCCGATAACATCGTCG
(XhoI)

oVCU375

AGATCTGGAAAATGTGCAAGCCGGACAAGCA
(BglII)
CTCGAGTTACCTGCCTTCCCCGATAACATCGT
(XhoI)
AGATCTGGCAGAAAATAATGCCAATGTCGCA
(BglII)
CTCGAGTTACCAGTTTTTATCCAAGCCTTTGAG
(XhoI)
AGATCTGGACATTACCGTGTACAACGGCCAA
(BglII)
CTCGAGTTATTTCATACCGGCTTGCTCAAGCAG
(XhoI)
AGATCTGGTGATAGAGTCAGGAAATGTTATCGA
(BglII)
CTCGAGTTAATTCAATTCAAACTTGACGGGGAC
(XhoI)

oVCU376
oVCU377
oVCU378
oVCU379
oVCU380
oVCU381
oVCU382
a
b
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tbpA
plug
tbpA
plug
tbpA
plug
fetA
plug
fetA
plug
fbpA
fbpA
tonB
tonB

Underlined nucleotides indicate alanine-encoding sequences and novel restriction sites
Underlined nucleotides represent engineered restriction sites for directional subcloning
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Table 5. Gene specific oligonucleotides

Primer

Oligonucleotide sequence (5’-3’)

Target

Non-mutagenic tbpA plug-specific primers
oVCU334
oVCU335

AAGCTTGTGAAATAAGCACGGCTGCCG
GAAGCGGTTGGGGCCCGTGTAGTCTCG

tbpA
tbpA

Revertant analysis – tbpB specific primers
oVCU136

ATGAACAATCCATTGGTGAATC

oVCU141

GCCGCCGCTCAAAGAAGAC

oVCU265
oVCU266
GC556

GAATTGGGTTTCCGCTTTTTG
GGAAGCCTTGCCGCTCCAGCT
CACCGCAAATGGCAATG

oVCU267

TCCATTGCCGGATTCAACTGTTGC

tbpB
upstream
tbpB
upstream
tbpB middle
tbpB middle
tbpB
downsteam
tbpB
downsteam

Revertant analysis – tbpA specific primers
oVCU272

GATTAGGGAAACACTATGCA

TfBP21

CCGATGTAGTGCCGTTTGTT

TfBP13
TfBP28
TfBP16

GGTCGTGGCTGTTCCGCCCG
AAATCCAGCCAGTCGGCAGG
GTACGGCTGGCGGTCGGGCG

oVCU291

CGCCGTCTGAAGCCTTTCAG

tbpA
upstream
tbpA
upstream
tbpA middle
tbpA middle
tbpA
downstream
tbpA
downstream
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CHAPTER 3 – ANALYSIS OF TBPA PLUG IRON BINDING AND
IDENTIFICATION OF RESIDUES REQUIRED FOR
TRANSFERRIN-IRON ACQUISITION BY NEISSERIA
GONORRHOEAE
I. Introduction
Neisseria species do not produce or secrete siderophores (6, 131, 235). Instead
they have the ability to utilize human transferrin (6, 18, 111, 131, 138), lactoferrin (6, 18,
111, 131), and hemoglobin (6, 138) through the expression of high-affinity receptors for
these host iron-binding proteins. Models of iron acquisition mediated by these highaffinity receptors are based on the well-characterized TonB-dependent siderophore
transporters (Figure 1) (28, 40, 42, 43, 61, 62, 119).
All gonococcal clinical isolates are able to utilize human transferrin (138) through
expression of the transferrin-iron uptake system, composed of TbpA and TbpB. TbpA is
a TonB-dependent outer membrane transporter that is essential for iron uptake, while
TbpB is a surface-exposed lipoprotein that discriminates between apo- and holotransferrin (20, 50, 183, 184). Unlike TbpA, TbpB is not required for transferrin-iron
acquisition but makes the process more efficient (4). Although TbpA has not yet been
crystallized, by analogy with characterized TonB-dependent transporters (Figure 2),
TbpA is predicted to form two distinct domains (Figure 3). The C-terminal β-barrel
domain, comprised of 22 transmembrane-spanning β-strands, likely functions as a
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channel for iron transport. The N-terminal plug domain is predicted to fold up within the
β-barrel domain to occlude the pore.
Characterized TonB-dependent transporters (Figure 2) serve as a paradigm for the
transferrin-iron uptake system, but the TbpB lipoprotein component and the requirement
for iron removal from transferrin are unique to this system. The precise mechanism by
which TbpA mediates iron internalization has not been elucidated. However, the
mechanism of iron acquisition through TbpA is unique in that the transferrin receptor
must bind holo-transferrin, remove iron from transferrin, transport iron across the outer
membrane, and release apo-transferrin at the cell surface. Thus, elucidation of the
detailed mechanism of transferrin-iron acquisition through TbpA would represent a
significant step towards characterization of a novel system for the acquisition of iron in
Neisseria gonorrhoeae.
Previous studies suggested that the TbpA plug domain plays a role in iron
internalization (243); however, the precise mechanism was not defined. We hypothesize
that the plug domain of TbpA functions in multiple steps of transferrin-iron uptake.
Specifically, we hypothesize that iron coordination by the TbpA plug domain is critical
for iron removal from transferrin, iron binding, and iron transport through the outer
membrane. The overall goal of this work was to demonstrate iron binding by the TbpA
plug domain and determine the mechanism of iron acquisition through TbpA, specifically
with respect to the contribution of the plug.

II. Results
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A. Gonococcal TbpA plug binds iron in vitro
To determine whether the neisserial TbpA plug domain binds iron, in vitro iron
binding assays were carried out (Figure 5). Recombinant, gonococcal FbpA, the
characterized periplasmic iron binding protein, serves as the positive control for iron
binding, while gonococcal ExbB, the cytoplasmic membrane protein of TonB complex,
serves as the negative control for iron binding. Recombinant gonococcal TbpA plug
bound significant levels of iron compared to the ExbB negative control, as was observed
for the FbpA positive control. Interestingly, the TbpA plug domain bound significantly
higher levels of iron than FbpA (P ≤ 0.02). These data indicate that the gonococcal TbpA
plug domain binds iron in vitro and likely plays a significant role in iron coordination and
transport in vivo.
B. Site-directed alanine substitution mutagenesis
Since the TbpA plug bound iron, putative iron-coordinating residues were
identified throughout this domain. The TbpA plug domain is highly conserved among
bacteria expressing the transferrin-iron acquisition system (45). An amino acid sequence
alignment of the TbpA plug from a variety of bacterial pathogens is shown in Figure 6.
The plug domain of TbpA contains several conserved sequence motifs, some of which
have potential iron-coordinating residues similar to those that coordinate iron in human
transferrin (88) and bacterial ferric binding protein A (FbpA) (214). Having shown iron
coordination by the plug, we hypothesize that potential iron-coordinating residues
function to remove iron from transferrin and transport iron through the outer membrane.
To test this hypothesis, site-directed, alanine substitution mutagenesis of conserved,
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Figure 5. Recombinant gonococcal TbpA plug binds iron in vitro. His-tagged,
recombinant FbpA (+), TbpA plug, and ExbB (−) proteins were expressed and purified.
Standardized levels of recombinant protein were bound to Ni-NTA agarose resin,
incubated with 55FeCl3 to determine total iron binding. Non-specific counts were
determined in two ways: (1) incubation in the presence excess cold Fe(NO3)3 competitor
and (2) incubation in the absence of recombinant protein. Levels of non-specific iron
binding were subtracted from total iron binding to determine specific iron binding by
recombinant proteins. These data are reported as specific counts per minute (CPM)
standardized to μg of recombinant proteins. Each bar represents the average of at least
three independent experiments, each performed in quadruplicate. Standard deviation is
represented by error bars. *, P ≤ 0.005 indicates significance difference from
recombinant ExbB(−) protein.
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potential iron-coordinating residues within the TbpA plug domain was performed. We
selected the EIEYE conserved sequence motif, shown in Figure 6, for analysis because
of the abundance of potential iron-coordinating residues, but more importantly, because
the region immediately upstream was shown to be critical for transferrin utilization (243).
We successfully generated six alanine substitution mutants: four single mutants at amino
acids 118 (E), 120 (E), 121 (Y), and 122 (E), one double mutant at amino acids 120 (E)
and 121 (Y), and one triple mutant at amino acids 120–122 (EYE). These alanine
substitution mutants are identified by their strain names (MCV250 – MCV261), but for
clarity, are also identified by the amino acid substitutions (Table 2).
C. Alanine substitution mutants express full-length TbpA and TbpB and bind
transferrin to the cell surface
To determine if alanine mutagenesis of the TbpA plug domain disrupted TbpA
protein expression and to ensure that TbpB expression was similar to the parental strain,
Western blot analyses were carried out (Figure 7). In panel A, expression of TbpA and
TbpB by the alanine substitution mutants in the FA19 (TbpB+) background was
evaluated. All alanine substitution mutants in this background expressed wild-type levels
of both TbpA and TbpB. In panel B, expression of TbpA and TbpB by the alanine
mutants in the FA6905 (TbpB−) background was evaluated. Alanine substitution
mutants in this background expressed wild-type levels of TbpA and did not express
TbpB, as was detected in the FA6905 parental control. We conclude that site-directed,
alanine substitution mutagenesis does not disrupt TbpA protein expression in any of the
mutants.
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Figure 6. Sequence alignment of TbpA plug domains from bacterial pathogens. The
first two letters preceding the amino acid sequences represent the genus and species name
of the bacterial pathogen: Ng, Neisseria gonorrhoeae; Nm, Neisseria meningitidis; Hi,
Haemophilus influenzae; Ap, Actinobacillus pleuropneumoniae; and Mc, Moraxella
catarrhalis. The subsequent numbers or letters represent the bacterial strain selected for
analysis. The sequences represent mature TbpA plug domains and the amino acids are
numbered accordingly to the right of the sequence. Dots indicate identical amino acids,
dashes represent positions in which gaps were introduced in the alignment, and letters
indicate the specific amino acid changes. Amino acids, in bold type and underlined,
represent potential iron-coordinating residues. These amino acids coordinate iron in
human transferrin (YHD) (88) and bacterial ferric binding protein A (YHE) (214). The
box indicates the conserved sequence motif selected for site-directed, alanine substitution
mutagenesis at amino acids 118 (E), 120 (E), 121 (Y), and 122 (E).
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Figure 7. Alanine substitution mutants express wild-type levels of TbpA and TbpB
by Western blot. Iron-stressed gonococci were lysed and standardized to a constant cell
density. Whole-cell lysates were separated by SDS-PAGE and then transferred to
nitrocellulose membranes. Blots were probed with anti-TbpA (α-TbpA) or anti-TbpB
(α-TbpB) polyclonal antibodies. Each lane is labeled according to the strain name with
amino acid substitutions in parentheses. Panel A shows alanine substitution mutants in
the FA19 (TbpB+) background, while panel B shows alanine substitution mutants in the
FA6905 (TbpB−) background. Controls include FA19 (positive control, TbpA+ TbpB+),
FA6905 (TbpA+ TbpB−), and FA6815 (negative control, TbpA− TbpB−).
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In addition to protein expression, TbpA surface exposure and transferrin binding
were also evaluated. To determine surface exposure and transferrin binding, solid-phase
transferrin binding assays, in which whole gonococcal cells were spotted to a
nitrocellulose membrane and probed with HRP-labeled transferrin, were performed
(Figure 8). In panel A, cell surface transferrin binding was evaluated for alanine
substitution mutants in the FA19 (TbpB+) background. Although not quantitative, it is
clear that all alanine substitution mutants bound transferrin to the cell surface when
compared to the positive and negative controls. Similarly, panel B shows cell surface
transferrin binding by alanine substitution mutants in the FA6905 (TbpB−) background.
Again, all alanine substitution mutants in the TbpB− background maintained the ability to
bind transferrin to the cell surface compared to the positive and negative controls.
Overall, these results show that site-directed, alanine substitution mutagenesis does not
affect TbpA expression levels, surface exposure, or the ability of TbpA to bind human
transferrin to the cell surface.
D. Alanine substitution mutants bind transferrin with wild-type affinity and
capacity
Solid-phase transferrin binding assays are not quantitative; therefore, to determine
the transferrin binding affinity of the mutated TbpA proteins, whole-cell, equilibriumphase transferrin binding assays were carried out (Figure 9). Since both TbpA and TbpB
function in high-affinity transferrin binding, these assays were performed with only
alanine substitution mutants in the FA6905 (TbpB−) background. In this manner,
transferrin binding by TbpA, alone, could be assessed and quantitated. Panel A shows
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Figure 8. Alanine substitution mutants bind transferrin to the cell surface in solidphase transferrin binding assays. Whole, iron-stressed gonococci, standardized to a
constant cell density, were applied to nitrocellulose membranes and probed with HRPlabeled transferrin. Each lane is labeled according to the strain name with amino acid
substitutions in parentheses. Panel A shows the alanine substitution mutants in the FA19
(TbpB+) background, while panel B shows the alanine substitution mutants in the
FA6905 (TbpB−) background. Controls include FA19 (positive control, TbpA+ TbpB+),
FA6905 (TbpA+ TbpB−), and FA6815 (negative control, TbpA− TbpB−).
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transferrin binding by the single alanine substitution mutants in the FA6905 (TbpB−)
background, while panel B shows binding by the double and triple alanine substitution
mutants in the FA6905 (TbpB−) background. All the alanine substitution mutants bound
similar levels of transferrin compared to the parental control FA6905. Affinity and
capacity measurements were calculated from the equilibrium transferrin binding data.
These values, shown in Table 6, revealed that all alanine substitution mutants have
similar transferrin binding affinities and capacities to the parental control FA6905.
Overall these data support the solid-phase transferrin binding data, but specifically show
that mutagenesis does not have a quantitative effect on transferrin binding affinity or on
receptor capacity.
E. Double and triple alanine substitution mutants demonstrate decreased
transferrin-iron internalization
TbpA plays two major roles in the process of iron acquisition by the gonococcal
cell: transferrin binding and iron internalization. Transferrin binding was evaluated in the
alanine substitution mutants and found to be at wild-type levels. Iron acquisition, the
other major step in transferrin-mediated iron uptake, was also evaluated. This assay was
performed by incubating gonococci with 20% iron-saturated human transferrin and
specific iron uptake was measured (Figure 10). Strain FA6815 (TbpA− TbpB−) was
unable to internalize iron due to the absence of TbpA and therefore served as the negative
control in this assay. Although TbpB is not required for transferrin-iron uptake, it has
been shown to make the process of iron internalization more efficient (4), and these data
show that FA6905 (TbpB−) internalized iron around 50% of wild-type levels. Alanine
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Figure 9. Alanine substitution mutants bind transferrin at wild-type levels in
equilibrium-phase transferrin binding assays. Whole, iron-stressed gonococci were
mixed with various concentrations of 125I-labeled human transferrin (0-100 nM). Specific
transferrin binding was determined by subtracting nonspecific binding (with excess
competing unlabeled human transferrin) from total binding. Specific transferrin binding
is reported on the y-axis as nanograms of transferrin bound per microgram of total cell
protein (ng Tf/ μg TCP). Only strains in the FA6905 (TbpB−) background are shown in
order to evaluate specific transferrin binding attributable to TbpA. Each curve is labeled
according to the strain name with amino acid substitutions shown. Each point represents
an average and standard deviation of at least three independent experiments. Panel A
shows the single alanine substitution mutants, while panel B shows the double and triple
alanine substitution mutants. Controls include FA6905 (positive control, TbpA+ TbpB−)
and FA6815 (negative control, TbpA− TbpB−).
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Table 6. Affinity and capacity measurements for alanine substitution mutants
generated from equilibrium-phase transferrin binding assays

Strains

Phenotype

Kda (nM)

Capacity (# receptors/μg TCP)b

FA6905
MCV251
MCV253
MCV255
MCV257
MCV259
MCV261

TbpA+, TbpB−
TbpA E118A, TbpB−
TbpA E120A, TbpB−
TbpA E121A, TbpB−
TbpA E122A, TbpB−
TbpA EY120AA, TbpB−
TbpA EYE120AAA, TbpB−

10.7 ± 2.9
9.2 ± 1.8
9.4 ± 1.4
6.8 ± 1.1
9.2 ± 2.1
11.2 ± 1.9
6.0 ± 1.2

1.67 × 108
1.53 × 108
2.37 × 108
1.65 × 108
1.32 × 108
1.19 × 108
1.10 × 108

a

b

Kd, capacity, and standard error calculated with Grafit software
TCP, total cell protein was determined by bicinchoninic acid (BCA) assay
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substitution mutants in the FA6905 (TbpB−) background were tested to determine the
specific contribution of TbpA in the process of iron internalization (Figure 10, panel A).
All single alanine substitution mutants in the FA6905 (TbpB−) background internalized
similar amounts of iron compared to the FA6905 parental control. However, the double
and triple alanine substitution mutants had significantly decreased iron internalization (P
≤ 0.01) when compared to the FA6905 parental control. Specifically, the double alanine
substitution mutant (MCV259) internalized approximately 50% less iron than FA6905,
while the triple alanine substitution mutant (MCV261) internalized approximately 80%
less iron than FA6905. These data show that the single alanine substitution mutants bind
transferrin with a wild-type affinity and internalize iron at a similar rate as wild-type.
While the double and triple alanine substitution mutants had wild-type transferrin binding
affinities, they demonstrated a significant decrease in iron internalization. Alanine
substitution mutants in the FA19 (TbpB+) background were evaluated in panel B. All
single alanine substitution mutants in the FA19 (TbpB+) background internalized similar
amounts of iron compared to the FA19 parental control. However, the double and triple
alanine substitution mutants still demonstrated a significant decrease in iron
internalization (P ≤ 0.01) when compared to the FA19 parental control, but the presence
of TbpB resulted in increased iron uptake by about 50% in both mutants. These results
suggest that the wild-type sequence at residues 120–122 (EYE) facilitates efficient iron
internalization.
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Figure 10. Double and triple alanine substitution mutants demonstrate decreased
iron internalization in transferrin-iron uptake assays. Iron-stressed gonococci were
incubated with 55Fe-labeled human transferrin. Specific iron uptake was measured in
picomoles (pmols) of iron internalized after 30 minutes. Each bar represents the mean of
at least six independent experiments and is labeled according to the strain name with
amino acid substitutions in parentheses. Panel A shows the alanine substitution mutants
in the FA6905 (TbpB−) background, while panel B shows the alanine substitution
mutants in the FA19 (TbpB+) background. Controls include FA19 (positive control,
TbpA+ TbpB+), FA6905 (TbpA+ TbpB−), and FA6815 (negative control, TbpA−
TbpB−). Standard deviations are represented by error bars. *, P ≤ 0.01 indicates
significance from both FA19 and FA6905.
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F. Triple alanine substitution mutant only utilizes transferrin as a sole iron
source in the presence of TbpB
Since the double and triple alanine substitution mutants had a significant decrease
in iron internalization, the ability of these mutants to utilize human transferrin as a sole
iron source was evaluated. To test this, transferrin-iron utilization growth assays, in
which gonococci were grown on CDM supplemented with 30% iron-saturated human
transferrin as the sole iron source, were carried out (Figure 11). Alanine substitution
mutants in both the FA19 (TbpB+) and FA6905 (TbpB−) backgrounds were tested. The
single alanine substitution mutants in both backgrounds maintained the ability to utilize
transferrin as a sole source of iron. In addition, although the double alanine substitution
mutants (MCV258 and MCV259) had significantly decreased iron internalization, these
mutants were able to utilize transferrin-bound iron for growth in both the presence and
absence of TbpB. The triple alanine substitution mutant in the FA19 (TbpB+)
background (MCV260), despite its decreased iron internalization, maintained the ability
to utilize transferrin as a sole iron source. However, consistent with the significant
decrease in iron internalization, the triple alanine substitution mutant in the FA6905
(TbpB−) background (MCV261) was unable to utilize transferrin, as shown in Figure 11.
These results suggest that TbpB has the ability to compensate for the defect observed in
the triple alanine substitution mutant. Overall, these data suggest that residues 120–122
(EYE) of the TbpA plug domain are critical for optimal iron internalization from
transferrin, but the function provided by this conserved plug domain motif can be
compensated for by the presence of TbpB.
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Figure 11. Triple alanine substitution mutant utilizes transferrin as a sole iron
source in transferrin utilization growth assays only in the TbpB-positive
background. Gonococcal strains were grown on CDM agarose plates containing 30%
iron-saturated human transferrin as a sole iron source. The ability of mutants to utilize
transferrin as a sole source of iron was evaluated by growth at 37oC with 5% CO2 for 24
hours. Strains are labeled according to the strain name with specific amino acid
substitutions in parentheses. Controls include FA19 (positive control, TbpA+ TbpB+),
FA6905 (TbpA+ TbpB−), FA6747 (negative control, TbpA− TbpB+), and FA6815
(negative control, TbpA− TbpB−).
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Since these assays were carried out using 30% iron-saturated transferrin, the
growth phenotypes of the alanine substitution mutants in the presence of a variety of iron
saturations ranging from 5% – 80% were determined (Table 7). The single and double
alanine substitution mutants in both backgrounds maintained the ability to utilize
transferrin at all the transferrin-iron saturations tested. Similar to the results in Figure 11,
the triple alanine substitution mutant in the FA19 (TbpB+) background (MCV260)
maintained the ability to utilize transferrin at all the transferrin-iron saturation levels.
However, the triple alanine substitution mutant in the FA6905 (TbpB−) background
(MCV261) was unable to utilize transferrin regardless of the level of iron saturation.
These data suggest that TbpA with alanine substitutions at residues 120–122 (EYE) is
completely unable to utilize transferrin and that the defect in transferrin utilization is not
due to inefficiency at low iron saturation levels. Furthermore, these data imply that the
compensatory function provided by TbpB is not due solely to the ability of TbpB to
specifically bind the ferrated form of transferrin.
G. MCV261 is unable to utilize transferrin in the presence of exogenous TbpB
In an attempt to characterize the compensatory function provided by TbpB,
transferrin-iron uptake assays were carried out in the presence of recombinant, full-length
TbpB (Figure 12) and FA6747 (TbpA− TbpB+) total membrane preparations (TMP)
(data not shown). We hypothesized that if the TbpA triple alanine substitution mutant
had a defect in iron removal from transferrin that TbpB was able to compensate for, then
perhaps exogenous TbpB could provide the stripping function thereby allowing MCV261
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Table 7. Phenotypes of alanine substitution mutants in transferrin-iron utilization
growth assays

Strain

Amino acid substitution

Iron-saturated transferrin*
5%

FA19
FA6905
FA6747
FA6815
MCV250
MCV251
MCV252
MCV253
MCV254
MCV255
MCV256
MCV257
MCV258
MCV259
MCV260
MCV261

TbpA+, TbpB+
TbpA+, TbpB− (ΔtbpB)
TbpA− (tbpA::mTn3cat), TbpB+
TbpA−, TbpB− (tbpB::Ω)
TbpA E118A, TbpB+
TbpA E118A, TbpB− (ΔtbpB)
TbpA E120A, TbpB+
TbpA E120A, TbpB− (ΔtbpB)
TbpA Y121A, TbpB+
TbpA Y121A, TbpB− (ΔtbpB)
TbpA E122A, TbpB+
TbpA E122A, TbpB− (ΔtbpB)
TbpA EY120AA, TbpB+
TbpA EY120AA, TbpB− (ΔtbpB)
TbpA EYE120AAA, TbpB+
TbpA EYE120AAA, TbpB− (ΔtbpB)

+
+
−
−
+
+
+
+
+
+
+
+
+
+
+
−

10% 30%
+
+
−
−
+
+
+
+
+
+
+
+
+
+
+
−

+
+
−
−
+
+
+
+
+
+
+
+
+
+
+
−

50% 80%
+
+
−
−
+
+
+
+
+
+
+
+
+
+
+
−

*, Transferrin-iron utilization growth assays were carried out with CDM plates
supplemented with 5%, 10%, 30%, 50%, or 80% iron-saturated human transferrin

+
+
−
−
+
+
+
+
+
+
+
+
+
+
+
−
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(TbpB−) to function in transferrin-iron utilization. However, if the triple alanine
substitution mutant had a transport defect and maintained the ability to remove iron from
transferrin, then exogenous TbpB would not facilitate transferrin-iron utilization by this
mutant. Transferrin-iron internalization assays were carried out with MCV261 (TbpB−)
as described previously, but in the presence of recombinant TbpB or FA6747 (TbpA−,
TbpB+) total membrane preparations (TMP) at concentrations equivalent to the amount
of transferrin present. Results from both assays showed that neither recombinant TbpB
nor TbpB from total membrane preparations (TMP) were able to compensate for the
TbpA plug domain mutant in transferrin-iron uptake. It is likely that the function
provided by TbpB requires expression of TbpB within the same membrane as TbpA.
Thus, these data suggest that TbpA and TbpB function together to facilitate the removal
of iron from transferrin and transport of iron through the outer membrane.

III. Discussion
In order for gonococci to utilize transferrin-bound iron, TbpA must carry out two
major functions: iron removal from transferrin and iron transport through the outer
membrane. This study was designed to analyze the functional role of the TbpA plug
domain in this process and to test the hypothesis that the plug functions in ironcoordination and subsequent iron internalization. In vitro studies indicated that the plug
domain of TbpA functions in iron coordination. Single, double, and triple alanine
substitution mutagenesis of putative iron-coordinating residues within the TbpA plug
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Figure 12. Exogenous TbpB is unable to compensate for MCV261 (EYE120AAA) in
transferrin-iron uptake assays. Iron-stressed gonococci were incubated with 55Felabeled human transferrin in the presence (+ rTbpB) or absence (− rTbpB) of equal molar
amounts of recombinant TbpB (125μM). Specific iron uptake was measured in
picomoles (pmols) of iron internalized after 30 minutes. Each bar represents the mean of
three independent experiments and is labeled according to the strain name with amino
acid substitutions in parentheses. Controls include FA19 (positive control, TbpA+
TbpB+), FA6905 (TbpA+ TbpB−), and FA6815 (negative control, TbpA− TbpB−).
Standard deviations are represented by error bars.
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domain resulted in mutants that expressed wild-type levels of TbpA on the gonococcal
cell surface and bound transferrin with wild-type affinity and capacity. Furthermore, no
growth abnormalities were observed with any of the alanine substitution mutants
suggesting that the alanine mutagenesis had relatively little impact on the structure or
function of gonococcal TbpA. Previous studies, in which deletion and insertion
mutagenesis of TbpA were performed (22, 243), are in agreement with these data and
support the theory that gonococcal TbpA, like other TonB-dependent receptors (7, 24, 98,
102, 117, 140, 157), is resilient to various types of mutagenesis.
Analysis of the double and triple alanine substitution mutants in transferrin-iron
uptake assays revealed a significant defect in iron internalization. Furthermore, analysis
of the triple alanine substitution mutant in transferrin-iron utilization growth assays
revealed that this mutant was unable to utilize transferrin-bound iron in the absence of
TbpB. This suggests that the defect in the TbpA plug domain can be overcome by the
presence of TbpB. This phenomenon has been previously observed with insertion
mutations in putative loops 2, 9, and 11 of TbpA (243), suggesting that TbpA and TbpB
have redundant function(s). Similar to the triple alanine substitution mutant, the loop 2,
9, and 11 TbpA insertion mutants showed no defect in transferrin binding, but a defect in
transferrin-iron utilization in the absence of TbpB (243). Therefore, the function of TbpB
is not limited to transferrin binding and holo/apo-transferrin discrimination (20, 50, 183,
184), but also appears to play an additional role in the mechanism of transferrin-mediated
iron uptake. The compensatory function provided by TbpB suggests that TbpA and
TbpB work together to accomplish transferrin-iron uptake. Although not much is known
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about the specific interactions between TbpA and TbpB, it has been shown that both
gonococcal and meningococcal TbpB associate with TbpA (63, 64, 97, 210). The defect
in transferrin-iron uptake and utilization seen in the TbpA triple alanine substitution
mutant could be attributed to either a defect in iron removal from transferrin, iron binding
by the plug, and/or iron transport through the β-barrel. Therefore TbpB may provide one
or more of these functions in wild-type gonococci. Since TbpB is a surface-exposed
lipoprotein, it is not likely to compensate for iron transport through the TbpA β-barrel,
but it may function in iron removal from transferrin by an unknown mechanism.
As mentioned previously, gonococcal TbpB is not typically required for
transferrin utilization, but in the case of the TbpA triple alanine substitution mutant,
TbpB is required for iron acquisition from transferrin. This dependence on TbpB
function is also observed in Neisseria meningitidis strain B16B6, which expresses a low
molecular weight class of the transferrin binding proteins. In B16B6, iron acquisition
from human transferrin requires TbpB (85), which is most likely due to the lack of
critical regions in the TbpA from this strain. Meningococcal TbpA from B16B6 shares
only 75% identity to gonococcal TbpAs (45) and shows sequence and length diversity
within the exposed loops (45, 163). These data suggest that there are multiple domains
within TbpA and TbpB that are important in transferrin-mediated iron acquisition.
Cumulatively, our data (160, 243) demonstrate that disruption of one or more epitopes
prevents TbpA function in the absence of TbpB. These domains may similarly be
lacking or nonfunctional in meningococcal strain B16B6.
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Our data demonstrate that the TbpA plug domain binds iron and residues 120–122
(EYE) of the TbpA plug domain are critical for transferrin-iron acquisition. This may be
due to alteration of an iron binding site, which may promote iron removal from
transferrin, subsequent iron binding by the plug, and transport through the outer
membrane. It has been shown that the plug domain of the E. coli TonB-dependent
transporter FepA binds directly to its ligand, ferric-enterobactin, in the absence of the βbarrel domain (222), which suggests the importance of the plug in ligand binding and
possibly transport. Oke et al. found that the neisserial TbpA plug domain was unable to
bind human transferrin (161). However, the TbpA plug domain most likely has a ligand
specificity for iron rather than transferrin. Although TbpA is a characterized transferrin
receptor, it is also an iron transporter. Therefore, TbpA has two ligand specificities
during the process of transferrin-mediated iron internalization. It is important to note
that, although residues 120–122 (EYE) of the TbpA plug domain are clearly involved in
transferrin-mediated iron acquisition, others may be involved as well.
Figure 13 shows a homology model for the gonococcal TbpA plug domain, which
was derived from comparison with the known crystal structure of the homologous plug
domain of the ferric-enterobactin transporter, FepA. The positions of amino acids 120
(E), 121 (Y), and 122 (E), mutated in the current study, are shown as ball and stick
representations. Interestingly, this conserved motif is located near the bottom of the plug
in this model. The position of this critical domain relative to the surface-exposed
opening of the barrel (top) is consistent with the hypothesis that the plug coordinates iron
via ligands from distant amino acid residues within the plug. Alternatively, iron may be
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Figure 13. Predicted structural model of N. gonorrhoeae TbpA plug domain. The
mature N. gonorrhoeae TbpA plug domain (amino acids 1-162) was aligned with the
homologous sequence of the E. coli FepA plug domain using the 3D-Jigsaw comparative
modeling program. The modeled region of TbpA spans from Thr25 (N-terminus) to
Thr151 (C-terminus). The resulting output file was visualized with First Glance in Jmol.
The image shown was captured and imported into Adobe Photoshop. The amino acids
120 (E), 121 (Y), and 122 (E) are represented by balls and sticks. Red indicates
hydrophobic atoms, while blue indicates hydrophilic atoms. Alpha helices and beta
strands are shown as ribbons, with arrowheads pointing toward the C-terminus. Random
coils are shown as smooth backbone traces.
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coordinated at multiple, different sites within the plug domain during transport through
the β-barrel. Our recombinant iron binding data may support this hypothesis in that the
TbpA plug domain binds more iron than FbpA, which may indicate more than one site of
iron coordination. It is also possible that these substitution mutants resulted in indirect
impacts within the plug domain leading to the plug’s inability to bind or transport iron.
Thus, the results of this study support the hypothesis that the plug domain coordinates
iron. This iron coordination is likely critical for transferrin-mediated iron internalization,
for mutations in possible coordination sites result in decreased iron uptake and losses in
TbpA-mediated transferrin utilization.
Overall, these studies provide insight into the mechanism of TbpA-mediated iron
acquisition. Further studies are necessary to determine the function of the TbpA plug
domain in respect to the multiple steps of transferrin-iron uptake: iron removal from
transferrin, iron binding and coordination, and iron transport through the outer
membrane. Further studies are also needed to address the function of TbpB in this
process of iron acquisition from transferrin. A better understanding of this mechanism
may reveal new sites within TbpA to target for vaccine development or to exploit for
treatment of gonococcal infection.
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CHAPTER 4 – ANALYSIS OF TBPA AND TBPB COOPERATION IN
TRANSFERRIN-IRON ACQUISITION BY NEISSERIA
GONORRHOEAE
I. Introduction
The gonococcal transferrin-iron acquisition system is composed of two dissimilar
proteins, TbpA and TbpB. TbpA is the TonB-dependent outer membrane iron transporter
required for transferrin-iron acquisition. However, the TbpB lipoprotein component is
not required for transferrin-iron internalization, but has been shown to make the process
more efficient (4). There have been few studies to address the mechanism by which
TbpB increases the efficiency of iron uptake; however, it has been shown that ligand
discrimination and holo-transferrin binding are not sufficient for this TbpB-dependent
increase in efficiency (56, 57).
TbpB is a bi-lobed structure with a C-terminal and N-terminal domain that both
function in transferrin binding (57). This was recently determined in a structure and
function analysis of mutants with hemagglutinin (HA) epitope insertions throughout the
length of TbpB (57). This study confirmed that TbpB was entirely surface-exposed and
that there were two distinct domains that function in high-affinity transferrin binding
(57). These HA epitope insertion mutants in TbpB have been fully characterized and
vary in their transferrin binding abilities (57).

104
Although TbpB is not required for transferrin-iron acquisition in the wild-type
receptor, there have been a number of characterized TbpA mutants that require TbpB for
function. These include one site-directed substitution mutant in the TbpA plug domain
(MCV260) (160) and HA epitope insertion mutants within the surface-exposed loops 2,
9, and 11 of TbpA (MCV527, MCV515, MCV519) (242). All of these mutants exhibited
identical phenotypes, in which the mutagenized TbpA maintained wild-type transferrin
binding, but was unable to utilize transferrin as a sole iron source in the absence of TbpB.
To date, TbpB has been shown to only function in transferrin binding and discrimination
(20, 50, 183, 184). Therefore, the ability of TbpB to compensate for defects in iron
internalization suggests that TbpB provides a novel function that does not directly pertain
to transferrin binding and discrimination. Thus, we hypothesize that specific domains of
TbpB may function in iron removal from transferrin, allowing for iron uptake and thus
restored function in transferrin utilization.
To address which domains in TbpB were required for the compensatory function,
TbpB was mutagenized in two gonococcal strains that require it for transferrin utilization
(MCV260 – EYE and MCV515 – L9HA). We hypothesized that these gonococcal
strains that require TbpB for function, despite having similar phenotypes, might exhibit
different defects in transferrin-iron acquisition. In addition, we hypothesized that TbpB
has various domains that are important for the observed compensatory functions.
Therefore, by combining characterized TbpA and TbpB mutations, specific regions of
TbpB required for TbpA-mediated transferrin utilization may be identified. Also, using
this approach, it may be possible to distinguish between phenotypically similar TbpA
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mutants, in an effort to elucidate the specific TbpA defects in transferrin-mediated iron
acquisition.

II. Results
A. Site-directed alanine substitution mutagenesis
TbpB has an N-terminal and C-terminal lobe, which both contain high-affinity
transferrin binding domains (57). Other regions within TbpB are highly conserved at the
amino acid sequence level (56, 57). One unique region of conservation is in the Cterminus and this region consists of two, adjacent cysteine residues (56, 57). To
investigate the role these residues play in transferrin-mediated iron acquisition, sitedirected alanine substitution mutagenesis was utilized to change the double cysteines to
double alanines (56). This mutation was generated in both FA19 (TbpA+) and FA6747
(TbpA−) backgrounds for analysis and resulting strains MCV845 and MCV846 are listed
in Table 2. It has been shown that cysteine residues can coordinate metal ions (105), and
therefore, these residues may play a role in the removal of iron from transferrin.
Additionally, these residues may be important for the compensatory function provided by
TbpB in either MCV260 (EYE120AAA) or MCV515 (L9HA). Therefore, in addition to
the previously characterized TbpB HA epitope insertion mutants (57), this cysteine
mutant was used for TbpA and TbpB combined mutagenesis, discussed below.
B. MCV845 expresses full-length TbpB that is capable of binding transferrin
To determine if site-directed mutagenesis of the TbpB conserved cysteine
residues disrupted TbpB protein expression levels or transferrin binding ability, Western
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blot analyses were carried out (Figure 14). Expression of TbpB and transferrin binding
ability were assessed by immunoblotting with anti-TbpB antibodies and HRP-labeled
transferrin, respectively. MCV845 (CC481AA, TbpA+) expressed wild-type levels of
TbpB and bound transferrin by Western blot. Therefore, site-directed alanine substitution
mutagenesis of cysteine residues does not disrupt TbpB protein expression. In addition,
TbpB is not subject to proteolytic degradation as a result of mutagenesis.
C. MCV846 binds transferrin with wild-type affinity and capacity
MCV845 (CC481AA, TbpA+) expressed wild-type levels of TbpB, but it was also
necessary to determine if site-directed mutagenesis affected TbpB surface exposure and
whole-cell transferrin binding ability. Thus, solid-phase transferrin binding assays were
used to assess surface expression of TbpB and transferrin binding to the gonococcal cell
surface (Figure 15). Whole-cell, iron-stressed gonococci were spotted to a nitrocellulose
membrane and probed with HRP-labeled transferrin to assess transferrin-binding
competent surface proteins. Although not quantitative it was clear that MCV845
(CC481AA, TbpA+) and MCV846 (CC481AA, TbpA−) expressed surface exposed and
transferrin binding competent TbpA and TbpB. Therefore, site-directed mutagenesis
does not disrupt TbpB overall protein expression levels, protein expression on the
gonococcal cell surface, or transferrin binding potential.
Since solid-phase transferrin binding assays are not quantitative, equilibriumphase transferrin binding assays were carried out to quantitate specific transferrin binding
affinity and capacity (Figure 16, Table 8). Since both TbpA and TbpB function in
transferrin binding, equilibrium-phase transferrin binding was assessed in the FA6747
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Figure 14. MCV845 expresses wild-type levels of TbpB and binds transferrin by
Western blot. Iron-stressed gonococci were lysed and standardized to a constant cell
density. Whole-cell lysates were separated by SDS-PAGE and then transferred to
nitrocellulose membranes. Blots were probed with anti-TbpB (α-TbpB) polyclonal
antibody (panel A) or HRP-transferrin (panel B). Each lane is labeled according to the
strain name with amino acid substitutions in parentheses. Controls include FA19
(positive control, TbpA+ TbpB+) and FA6815 (negative control, TbpA− TbpB−).
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Figure 15. Double cysteine mutants bind transferrin to the cell surface in solidphase transferrin binding assays. Whole, iron-stressed gonococci, standardized to a
constant cell density, were applied to nitrocellulose membranes and probed with HRPlabeled transferrin. Each lane is labeled according to the strain name with amino acid
substitutions shown below. Controls include FA19 (positive control, TbpA+ TbpB+),
FA6747 (TbpA− TbpB+), FA6905 (TbpA+ TbpB−), and FA6815 (negative control,
TbpA− TbpB−).
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(TbpA−) background (MCV846) to determine the transferrin binding ability of TbpB
only. From these studies it is clear that MCV846 (CC481AA, TbpA−) bound wild-type
levels of transferrin as shown in Figure 16. Affinity and capacity measurements
calculated from these equilibrium-phase transferrin binding data show that MCV846
exhibited wild-type transferrin binding affinity and capacity (Table 8).
D. MCV845 demonstrates decreased transferrin-iron internalization
Although TbpB is not required for transferrin-iron internalization, it does increase
the efficiency of iron uptake (4). Since the TbpB double cysteines may have a role in
iron removal from transferrin, this mutant may exhibit decreased efficiency in iron
internalization when compared to the wild-type. Thus, transferrin-iron internalization
assays were carried out in the FA19 (TbpA+) background (MCV845). Iron-stressed
gonococci were incubated with 20% iron-saturated human transferrin, and specific iron
uptake is shown in Figure 17. As mentioned previously, TbpB is known to increase the
efficiency of iron internalization and that was apparent with the FA6905 (TbpB−)
control, which internalized about 50% of wild-type FA19. In support of our hypothesis,
MCV845 (CC481AA, TbpA+) showed a significant decrease in iron uptake,
approximately 60% of wild-type FA19. Iron internalization by MCV845 was also
significantly greater than that of FA6905 (TbpB−) control. Thus, double cysteine
residues in the C-terminus of TbpB play an important role in increasing the efficiency of
transferrin-iron uptake, but replacement of the cysteine residues does not completely
abolish TbpB function. To further analyze the contribution these double cysteines play in
transferrin-mediated iron uptake, MCV845 (CC481AA, TbpA+) as well as other
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Figure 16. MCV846 binds transferrin at wild-type levels in equilibrium-phase
transferrin binding assays. Whole, iron-stressed gonococci were mixed with various
concentrations of 125I-labeled human transferrin (0-100 nM). Specific transferrin binding
was determined by subtracting nonspecific binding (with excess competing unlabeled
human transferrin) from total binding. Specific transferrin binding is reported on the yaxis as nanograms of transferrin bound per microgram of total cell protein (ng Tf/μg
TCP). Only MCV846, the TbpA− strain, is shown in order to evaluate specific
transferrin binding attributable to TbpB. Each curve is labeled according to the strain
name with amino acid substitutions shown. Each point represents the average and
standard deviation of at least three independent experiments. Controls include FA6747
(positive control, TbpA− TbpB+) and FA6815 (negative control, TbpA− TbpB−).
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Table 8. Affinity and capacity measurements for MCV846 generated from
equilibrium-phase transferrin binding assays

Stain

Phenotype

Kda (nM)

Capacityb (# receptors/μg TCP)

FA6747
MCV846

TbpA−, TbpB+
TbpA−, ΤbpB CC481AA

12.6 ± 0.6
13.1 ± 0.4

7.00 x 108
7.19 x 108

a

b

Kd, capacity, and standard error calculated with Grafit software
TCP, total cell protein was determined by bicinchoninic acid (BCA) assay
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Figure 17. MCV845 demonstrates decreased iron internalization in transferrin-iron
uptake assays. Iron-stressed gonococci were incubated with 55Fe-labeled human
transferrin. Specific iron uptake was measured in picomoles (pmols) of iron internalized
after 30 minutes. Each bar represents the mean of at least six independent experiments
and is labeled according to the strain name with amino acid substitution in parentheses.
Controls include FA19 (positive control, TbpA+ TbpB+), FA6905 (TbpA+ TbpB−), and
FA6815 (negative control, TbpA− TbpB−). Standard deviations are represented by error
bars. *, P ≤ 0.05 indicates significance from both FA19 and FA6905.
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previously characterized TbpB HA-epitope insertion mutants were used for TbpA and
TbpB combined mutagenesis and are discussed below. All the single TbpA and TbpB
mutations utilized for combined mutagenesis are described below.
E. TbpA and TbpB single mutants express transferrin binding competent, fulllength TbpB
To confirm previously described phenotypes, all single TbpA and TbpB mutants
used in combined mutagenesis were subjected to Western blot analysis to evaluate TbpB
protein expression and HRP-transferrin binding (Figure 18). HRP-transferrin binding by
Western blot assesses TbpB protein expression as well as transferrin binding ability.
Following SDS-PAGE the N-terminal high-affinity transferrin binding domain of TbpB
retains its transferrin binding ability. Therefore, HRP-transferrin probes for transferrin
binding by the N-terminus of TbpB. As previously observed (57, 160, 243), this study
confirmed that all single mutants expressed wild-type levels of TbpB. In addition,
transferrin binding phenotypes were also consistent with previous results (57, 243).
Mutations in the TbpA plug domain (MCV260 – EYE120AAA) and loop 9 of TbpA
(MCV515 – L9HA) were able to bind transferrin by Western blot, indicating the presence
of a wild-type, transferrin-binding competent TbpB. Similarly, MCV845 (CC481AA,
TbpA+) bound wild-type levels of transferrin by Western blot. TbpB HA epitope
insertion mutants showed varying levels of transferrin binding. HA epitope insertion into
position 3 of TbpB (MCV812 – HA3) caused a decrease in transferrin binding, while HA
epitope insertion into position 5 (MCV816 – HA5) abolished transferrin binding by
Western blot. These findings are consistent with previous studies and are not surprising
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Figure 18. Mutations in TbpA and TbpB do not affect TbpB protein expression or
transferrin binding by Western blot. Iron-stressed gonococci were lysed and
standardized to a constant cell density. Whole-cell lysates were separated by SDS-PAGE
and then transferred to nitrocellulose membranes. Blots were probed with anti-TbpB
(TbpB) polyclonal antibodies (top panel) or HRP-labeled transferrin (bottom panel).
Each lane is labeled according to the strain name and mutation. Controls include FA19
(positive control, TbpA+ TbpB+), FA6905 (TbpA+ TbpB−), and FA6815 (negative
control, TbpA− TbpB−).
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because positions 3 and 5 are both within the N-terminal high-affinity transferrin binding
domain of TbpB. As previously shown, HA epitope insertion into position 9 of TbpB
(MCV824 – HA9) caused no defect and wild-type levels of transferrin binding were
observed.
F. TbpA and TbpB single mutants bind transferrin to the cell surface
Transferrin binding and surface exposure were assessed by solid-phase transferrin
binding assays (Figure 19). HA epitope surface expression was also assessed by solidphase anti-HA antibody binding. Whole-cell, iron-stressed gonococci were spotted to
nitrocellulose membranes and probed with HRP-transferrin or an HRP-HA antibody. Dot
blot analysis confirmed HA epitope surface exposure; although, as previously shown, HA
epitope insertions were not equally accessible by HA antibody (57, 243). Unlike
transferrin binding by Western, cell-surface transferrin binding detects both TbpA- and
TbpB-mediated transferrin binding as well as transferrin binding by both domains of
TbpB. Thus, phenotypes observed by Western blot are masked in solid-phase assays by
the ability of both TbpB N-terminal and C-terminal domains ability to bind transferrin to
the cell surface. These data show that all single mutants express TbpA and TbpB on the
gonococcal cell surface and maintain the ability to bind transferrin. These studies show
that mutagenesis of TbpA or TbpB does not disrupt protein expression or transferrin
binding ability to the gonococcal cell surface.
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Figure 19. TbpA and TbpB single mutants bind transferrin and express HA
epitopes on the cell surface in solid-phase transferrin binding assays. Whole, ironstressed gonococci, standardized to a constant cell density, were applied to nitrocellulose
membranes and probed with HRP-labeled transferrin (top panel) or HRP-HA antibody
(bottom panel). Each lane is labeled according to the strain name with mutations shown
below. Controls include FA19 (positive control, TbpA+ TbpB+), FA6905 (TbpA+
TbpB−), and FA6815 (negative control, TbpA− TbpB−).
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G. TbpA and TbpB single mutants vary in ability to internalize iron from
transferrin
To analyze the ability of each mutant to internalize iron, transferrin-iron uptake
assays were carried out (Figure 20). For this assay, iron-stressed gonococci were
incubated with 20% iron-saturated human transferrin and specific iron uptake was
measured. As previously observed, FA6905 (TbpB−) was less efficient in iron uptake
and internalized about 42% of wild-type FA19. All of the mutants tested in iron uptake
assays had significant defects in iron internalization. As previously shown, MCV260
(EYE120AAA) internalized iron at 60% of wild-type FA19. The other TbpA mutant
tested in this assay was the HA-encoding epitope insertion into loop 9 of TbpA (MCV515
– L9HA). Although MCV515 (L9HA) has been shown to have the same phenotype as
the TbpA plug mutant, it is clear from the iron uptake data, that MCV515 (L9HA) has a
much greater defect in transferrin-iron internalization, only internalizing 15% of wildtype FA19. Although these mutants have similar growth phenotypes, they clearly have
different defects in transferrin-iron acquisition.
The various TbpB single mutants were also tested to evaluate how the efficiency
of iron uptake was affected. Although some of these mutants had been previously tested
and characterized, the studies presented here were performed and analyzed differently
than what was previously reported (57). Therefore, any differences observed in iron
uptake phenotypes from this study in comparison to the previous study (57) are attributed
to the way in which these assays were performed and these data were analyzed. The
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MCV845 (CC481AA, TbpA+) as previously shown only internalized 60% of iron
compared to wild-type FA19. HA epitope insertion mutants in the N-terminus of TbpB
at positions 3 and 5 (HA3 and HA5) resulted in significantly decreased iron uptake.
MCV812 (HA3) internalized about 40% of wild-type FA19, similar to the TbpB−
(FA6905) control. Overall, MCV812 (HA3) exhibited decreased transferrin binding and
an iron uptake efficiency similar to that of a TbpB− strain (FA6905). In contrast,
MCV816 (HA5), which had abolished transferrin binding by Western blot, demonstrated
iron uptake below that of a TbpB− (FA6905) strain, about 15% of wild-type FA19. Iron
uptake levels below 50% of wild-type were not expected as they suggest a defect in
TbpA. This mutant may express lower levels of TbpA, which could account for
significant decrease in iron uptake below TbpB− (FA6905) levels. The final TbpB HA
epitope insertion mutant, MCV824 (HA9), had an identical phenotype to MCV845
(CC481AA). MCV824 (HA9) exhibited wild-type transferrin binding and demonstrated a
decreased efficiency in transferrin-iron uptake, about 60% of wild-type FA19. Thus,
both mutations in the C-terminus of TbpB, CC481AA and HA9, caused similar defects
whereby TbpB still functioned in transferrin binding and contributes to the efficiency of
transferrin-iron uptake. Overall, these data illustrate the phenotypic diversity that these
mutations have on TbpA and TbpB function. Combined TbpA and TbpB mutagenesis,
discussed below, will allow us to determine specific domains in TbpB that are required
for compensatory functions and will help elucidate the mechanism of transferrin-iron
acquisition utilized by these mutants.
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Figure 20. TbpA and TbpB single mutants internalize varying levels of iron in
transferrin-iron uptake assays. Iron-stressed gonococci were incubated with 55Felabeled human transferrin. Specific iron uptake was measured in picomoles (pmols) of
iron internalized after 30 minutes. Each bar represents the mean of at least six
independent experiments and is labeled according to the strain name with mutations in
parentheses. Controls include FA19 (positive control, TbpA+ TbpB+), FA6905 (TbpA+
TbpB−), and FA6815 (negative control, TbpA− TbpB−). Standard deviations are
represented by error bars. *, P ≤ 0.05 indicates significance from FA19, while **
indicates significance from both FA19 and FA6905.
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H. Combined TbpA and TbpB mutagenesis
Combined TbpA and TbpB mutants were generated for the purpose of
determining regions of TbpA and TbpB critical for iron acquisition from transferrin. By
utilizing specific TbpA mutants that require TbpB for function, our goal was to determine
the functions required by TbpB for TbpA compensation. TbpA mutants, MCV260
(EYE120AAA) and MCV515 (L9HA), were both combined with MCV845 (CC481AA) to
generate strains MCV262 (EYE/CC) and MCV266 (L9/CC), respectively. Previous
mutagenesis and analyses were carried out in which MCV515 (L9HA) was combined
with various TbpB HA epitope insertion mutants (57). In a similar fashion, MCV260
(EYE120AAA) was combined with the various TbpB HA epitope insertion mutants:
MCV812 (HA3), MCV816 (HA5), and MCV824 (HA9). It was hypothesized that
MCV816 (HA5), which phenotypically resembles the TbpB− strain (FA6905) should not
compensate for either TbpA mutation. However, the TbpB mutants that exhibit an
intermediate phenotype, MCV845 (CC481AA), MCV812 (HA3), and MCV824 (HA9)
may or may not compensate for TbpA, depending on the role these regions play in
transferrin-mediated iron uptake.
I. Combined mutants express full-length TbpA and TbpB
Before determining the effects of mutagenesis on transferrin-iron acquisition,
these mutants were characterized to ensure that they expressed wild-type levels of TbpA
and TbpB. Therefore, these strains were subjected to Western blot analyses, for detection
of TbpA, TbpB, and HRP-transferrin binding (Figure 21). All combined mutants
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expressed wild-type levels of full-length TbpA and TbpB; therefore, combined
mutagenesis does not disrupt the expression of either transferrin binding protein.
Western blotting with HRP-transferrin, as mentioned previously, detects only transferrin
binding by the N-terminus of TbpB. Thus, these results only reflect transferrin binding
by TbpB present in each strain. These data show that combined mutagenesis does not
alter the transferrin binding phenotypes observed for the single TbpB mutants in Western
blot analysis.
J. Combined mutants bind transferrin to the cell surface
To ensure that these combined mutants expressed TbpA and TbpB on the
gonococcal cell surface, solid-phase transferrin binding assays were carried out (Figure
22). Iron-stressed, whole-cell gonococci were spotted to nitrocellulose membrane and
probed with HRP-labeled transferrin for detection of transferrin binding to the
gonococcal cell surface. Unlike Western blot analysis with HRP-transferrin, solid-phase
dot blots represent transferrin binding by TbpA and both binding domains of TbpB.
From this analysis, it was concluded that both TbpA and TbpB are surface exposed and
transferrin binding competent.
K. Combined mutants vary in ability to internalize iron from transferrin
To determine the effects of combined mutagenesis on iron internalization,
transferrin-iron uptake assays were performed, whereby gonococcal strains were
incubated with 20% iron-saturated human transferrin and specific iron uptake was
measured (Figure 23). Each combined mutant exhibited significantly lower levels of iron
internalization as compared to the parental control (FA19). Many of the mutants
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Figure 21. TbpA and TbpB combined mutants express wild-type levels of TbpA
and TbpB and bind transferrin by Western blot. Iron-stressed gonococci were lysed
and standardized to a constant cell density. Whole-cell lysates were separated by SDSPAGE and then transferred to nitrocellulose membranes. Blots were probed with antiTbpA (TbpA) (top panel), anti-TbpB (TbpB) (middle panel), or HRP-labeled transferrin
(HRP-Tf) (bottom panel). Each lane is labeled according to the strain name with
mutation shown below. Controls include FA19 (positive control, TbpA+ TbpB+),
FA6905 (TbpA+ TbpB−), and FA6815 (negative control, TbpA− TbpB−).
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Figure 22. TbpA and TbpB combined mutants bind transferrin and express HA
epitope on the cell surface in solid-phase transferrin binding assays. Whole, ironstressed gonococci, standardized to a constant cell density, were applied to nitrocellulose
membranes and probed with HRP-labeled transferrin (top panel) or HRP-HA antibody
(bottom panel). Each lane is labeled according to the strain name with mutations shown
below. Controls include FA19 (positive control, TbpA+ TbpB+), FA6905 (TbpA+
TbpB−), and FA6815 (negative control, TbpA− TbpB−).
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exhibited even lower levels of iron uptake than the TbpB− control (FA6905). Therefore,
wild-type TbpA and TbpB are required for efficient iron uptake and the different TbpB
defects cause variations in the levels of transferrin-iron internalization.
L. Combined mutants utilize transferrin only when TbpB is transferrin-binding
competent
Transferrin-iron utilization growth assays were carried out to determine if these
decreases in iron internalization were substantial enough to prevent utilization of
transferrin as a sole iron source. For these assays, gonococcal strains were grown on
CDM supplemented with 30% iron-saturated transferrin as the sole iron source (Table 9).
Growth phenotypes of the single and combined mutants are summarized in Table 9. The
TbpA single mutants, as shown previously (160, 243), were only able to utilize
transferrin in the FA19 (TbpB+) background. Thus, MCV260 (EYE120AAA) and
MCV515 (L9HA) are dependent on TbpB for transferrin utilization. The TbpB single
mutants were able to utilize transferrin, as expected, because they express wild-type
TbpA. Despite the significantly low levels of iron internalization, all of the combined
mutants, with the exception of MCV264 (EYE/HA5), were able to utilize transferrin as a
sole iron source. These data show that in order for TbpB to compensate for these TbpA
defects, the function of the N-terminal transferrin binding domains of TbpB is required.
Compensation, up to this point, has been defined as the ability of mutant
gonococcal strains to grow, in the presence of TbpB, with transferrin provided as the sole
iron source. If, however, we look at the ability of TbpB to compensate in terms of iron
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Figure 23. TbpA and TbpB combined mutants internalize varying levels of iron in
transferrin-iron uptake assays. Iron-stressed gonococci were incubated with 55Felabeled human transferrin. Specific iron uptake was measured in picomoles (pmols) of
iron internalized after 30 minutes. Each bar represents the mean of at least six
independent experiments and is labeled according to the strain name with mutations in
parentheses. Controls include FA19 (positive control, TbpA+ TbpB+), FA6905 (TbpA+
TbpB−), and FA6815 (negative control, TbpA− TbpB−). Standard deviations are
represented by error bars. *, P ≤ 0.05 indicates significance from FA19, while **
indicates significance from both FA19 and FA6905.
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Table 9. Phenotypes of TbpA and TbpB combined mutants in transferrin-iron
utilization growth assays

Strain

Phenotype

Growth
phenotype

Reference

+
+
−
−

This study
This study
This study
This study

This study
(160)
This study
(160)
This study
(56)
This study
(57)
This study
(57)
This study
(57)
This study
(243)
This study
(243)
(243)
(243)
(243)
(243)

Controls
FA19
FA6905
FA6747
FA6815

TbpA+, TbpB+
TbpA+, TbpB−
TbpA−, TbpB+
TbpA−, TbpB−
Single mutations

MCV260

TbpA EYE120AAA, TbpB+

+

MCV261

TbpA EYE120AAA, TbpB−

−

MCV845

TbpA+, TbpB CC481AA

+

MCV812

TbpA+, TbpB HA3175

+

MCV816

TbpA+, TbpB HA5327

+

MCV824

TbpA+, TbpB HA9660

+

MCV515

TbpA L9HA750, TbpB+

+

MCV516

TbpA L9HA750, TbpB−

−

MCV519
MCV520
MCV527
MCV528

TbpA L11HA843, TbpB+
TbpA L11HA843, TbpB−
TbpA L2HA229, TbpB+
TbpA L2HA229, TbpB−

+
−
+
−

Combined mutations
MCV262

TbpA EYE120AAA, TbpB
CC481AA

+

MCV263

TbpA EYE120AAA, TbpB HA3175

+

This study
(DeRocco
unpublished)
This study

MCV264

TbpA EYE120AAA, TbpB HA5327

−

MCV265

TbpA EYE120AAA, TbpB HA9660

+

MCV266

TbpA L9HA750, TbpB CC481AA

+

MCV828
MCV830
MCV833
MCV834

TbpA L9HA750, TbpB HA3175
TbpA L9HA750, TbpB HA5327
TbpA L9HA750, TbpB HA8607
TbpA L9HA750, TbpB HA9660

+
−
−
+
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(DeRocco
unpublished)
This study
(DeRocco
unpublished)
This study
(DeRocco
unpublished)
This study
(DeRocco
unpublished)
(57)
(57)
(57)
(57)
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internalization, we observed that specific domains of TbpB were required for
compensation of some TbpA mutants, but not others. Figure 24 shows the relative levels
of iron uptake by all the single and combined mutants. Both TbpA mutations
(EYE120AAA and L9HA) were combined with MCV845 (CC481AA). Interestingly,
MCV262 (EYE/CC) resulted in a decrease in iron internalization that was significantly
greater than the additive effects of either single mutation alone (P ≤ 0.02). However,
MCV266 (L9/CC) did not exhibit a significant decrease in the efficiency of iron uptake
when compared to each single mutation in isolation. In contrast, the TbpB CC481AA
mutation actually increased TbpA (L9HA)-mediated iron internalization (MCV266 –
L9/CC). Therefore, the double cysteine residues in TbpB are required for compensatory
function in MCV260 (EYE120AAA), whereas, they play no role in compensation for the
MCV515 (L9HA). These data support the hypothesis that these TbpA mutants have
different defects and specific domains of TbpB are required for different compensatory
functions. This is also supported by the data seen in comparing MCV262 (EYE/CC) and
MCV265 (EYE/HA9). Single mutants MCV845 (CC481AA) and MCV824 (HA9) have
identical phenotypes; however, when these mutations are combined with the MCV260
(EYE120AAA), they exhibit different levels of TbpB-mediated compensation. Despite the
fact that these mutations in TbpB cause identical defects, the compensatory functions
differ, such that the CC481AA mutation in TbpB does not allow for compensation of the
EYE120AAA mutation in TbpA (MCV262 – EYE/CC), but the HA9 mutation in TbpB
does (MCV265 – L9/CC). Although the specific mechanism by which TbpB
compensates for TbpA defects has not been determined, we have identified specific
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Figure 24. Comparative analysis of transferrin-iron uptake by single and combined
TbpA and TbpB mutants. Iron-stressed gonococci were incubated with 55Fe-labeled
human transferrin. Specific iron uptake was measured in picomoles (pmols) of iron
internalized after 30 minutes. Each bar represents the mean of at least six independent
experiments and is labeled according to the strain name with mutations in parentheses.
Controls include FA19 (positive control, TbpA+ TbpB+), FA6905 (TbpA+ TbpB−), and
FA6815 (negative control, TbpA− TbpB−). Standard deviations are represented by error
bars. *, P ≤ 0.02 indicates significance from both single mutants.
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regions of TbpB that are critical for TbpA compensation.

III. Discussion
Transferrin-iron acquisition by Neisseria gonorrhoeae is mediated by the
transferrin binding proteins, TbpA and TbpB. In the wild-type gonococcus, TbpA is
required for transferrin-iron acquisition, while TbpB is not essential (4). However, there
have been a number of TbpA mutants that require TbpB for transferrin utilization (160,
243), suggesting that TbpB can compensate for selected TbpA defects and plays an active
role in the process of transferrin-iron acquisition. This study was designed to analyze the
compensatory role of TbpB in transferrin-iron acquisition and to identify regions critical
for its compensatory functions. Our approach involved the combination of various TbpB
mutations with TbpA mutations, which resulted in TbpA that required TbpB for
transferrin utilization. The results presented here suggest that combined mutagenesis
does not significantly impact the structure or surface localization of the transferrin
binding proteins. This study is in agreement with other studies in which gonococcal
TbpA and TbpB were subjected to substitution (160), insertion (57, 243), deletion (22),
and combined mutagenesis (57) and shows that the transferrin binding proteins are
resilient to many types of mutagenesis.
All TbpA and TbpB combined mutations caused a significant decrease in
transferrin-iron internalization by gonococcal mutant strains. Despite the decreased iron
internalization, most combined mutants maintained the ability to utilize transferrin as a
sole source of iron. Although unexpected, these data suggest that wild-type gonococci
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acquire iron from transferrin at levels that exceed their need for growth under laboratory
conditions, and mutants capable of acquiring iron at 12% of wild-type strains are still
capable of growth in vitro. Analysis and quantitation of specific iron uptake by each
mutant revealed subtle differences in phenotypes and compensatory functions attributable
to TbpB. Full compensation of TbpA-transferrin utilization required the function of both
high-affinity transferrin binding domains of TbpB. However, iron uptake data revealed
different domains of TbpB that compensate for specific defects in TbpA. Specifically,
the TbpB C-terminal double cysteines play a role in compensation for TbpA plug domain
defects (MCV262 – EYE/CC), while they have no role in compensating for TbpA L9HA
defects (MCV266 – L9/CC). Although MCV527 (L2HA) and MCV519 (L11HA) were
not tested in these combined mutagenesis studies, we would hypothesize that they would
be phenotypically similar to MCV515 (L9HA) in regard to TbpB compensation.
These findings support the hypothesis that the TbpA and TbpB interaction is
complex and multiple domains of these proteins cooperate in transferrin-iron acquisition.
Although the specific interaction between TbpA and TbpB is difficult to address in these
studies, these proteins have been shown to interact in various other studies (63, 64, 97,
210). The major function provided by TbpB that is critical for TbpA compensation is the
ability of the N-terminal and C-terminal domains to cooperate in high-affinity transferrin
binding. If the N-terminal high-affinity binding domain is not functional as observed in
MCV264 (EYE/HA5) and MCV830 (L9/HA5) (57), TbpB cannot compensate for TbpA.
The same is true if C-terminal transferrin binding is disrupted (MCV833 – L9/HA8) (57).
From these studies, another region of TbpB identified as important for compensation of
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TbpA-defective mutants is the two highly conserved C-terminal cysteine residues. These
double cysteines are conserved within TbpB among many bacterial pathogens (57),
suggesting their importance in transferrin-mediated iron acquisition. It has been shown
that cysteines in close proximity can coordinate metal ions (105) and even solubilize
insoluble metal complexes in solution (118). In wild-type TbpB, it is possible that the
double cysteines function in iron coordination or even in solubilizing iron, which may
contribute to the compensatory function observed with MCV260 (EYE120AAA).
Therefore, these double cysteines in TbpB may also contribute to the increased efficiency
provided by TbpB in the wild-type transferrin-iron acquisition system. Furthermore, if
the TbpA plug domain mutation (EYE120AAA) prevents iron coordination and therefore
iron removal and internalization, the double cysteines of TbpB may compensate for either
of these functions. Although the specific function that the TbpB double cysteines play in
the compensation of TbpA defects has not been determined, it is clear that they do
contribute to the efficiency of transferrin-iron acquisition as well as TbpB compensatory
function.
Overall these studies provide insight into the cooperation of TbpA and TbpB in
the mechanism of transferrin-iron acquisition. However, future studies are necessary to
determine the specific mechanism by which TbpB compensates for TbpA. This study has
identified regions in TbpB important in the efficient functioning of the wild-type
receptor, but also in TbpA compensation in defective receptors. Understanding the
mechanism of transferrin utilization and the critical components of the transferrin binding
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proteins could provide greater insight into development of novel antimicrobials as well as
identification of new vaccine targets.
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CHAPTER 5 – ANALYSIS OF A TONB-INDEPENDENT
MECHANISM OF TRANSFERRIN-IRON UTILIZATION BY
NEISSERIA GONORRHOEAE
I. Introduction
The transferrin binding proteins (TbpA and TbpB) of Neisseria gonorrhoeae
promote the efficient acquisition of iron from human transferrin. Characterization of
various site-directed and insertion mutations in these receptors have aided the
understanding of the mechanisms of transferrin-iron acquisition (22, 57, 126, 160, 243).
TbpA mutants that require TbpB for transferrin utilization have been discussed in the
previous chapters. These phenotypes highlight the importance of TbpB in the process of
transferrin-iron acquisition. Additionally, there are a number of TbpA mutants that are
unable to utilize transferrin even in the presence of TbpB (243). A subset of these
mutants regain the ability to utilize transferrin after 72 hours of incubation with human
transferrin provided as the sole iron source. The two mutants that exhibited this
phenotype contained HA epitope insertions within β-strand 16 (MCV523 – β16HA,
TbpB+) and loop 3 (MCV511 – L3HA, TbpB+) of TbpA (242, 243). Both MCV511
(L3HA) and MCV523 (β16HA) expressed wild-type levels of TbpA (243). MCV511
(L3HA) but not MCV523 (β16HA) expressed the HA epitope on the gonococcal cell
surface, indicating that loop 3 was surface exposed, while β-strand 16 was not (243).
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TbpA of MCV511 (L3HA) was unable to bind human transferrin, while MCV523
(β16HA) bound transferrin with wild-type affinity and capacity (243). Both of these
mutants were unable to utilize transferrin in either FA19 (TbpB+) (MCV511 and
MCV523) or FA6905 (TbpB−) (MCV512 and MCV524) backgrounds (243). However,
upon 72 hours of incubation, both of these mutants in the FA19 background regained the
ability to utilize transferrin as a sole iron source. This reversion was specific to MCV511
(L3HA) and MCV523 (β16HA) as it did not occur in other mutants that were unable to
utilize transferrin. Furthermore, this phenotype was not transient, but allowed for
continued use of transferrin as the sole iron source over multiple generations.
The objective of this study was to determine the mechanism by which these
mutants reverted to a transferrin-positive growth phenotype. It is important to consider
this reversion mechanism in looking at TbpA and TbpB as vaccine candidates. It has
been shown that TbpA and TbpB are expressed by all clinical isolates of N. gonorrhoeae
(138), which implicates their importance in virulence. In addition, the gonococcal
transferrin-iron acquisition system is required to initiate infection in human challenge
experiments (49). Thus far, the components of the transferrin utilization system, TbpA
and TbpB, of N. gonorrhoeae have been identified as possible vaccine candidates.
However, if Neisseria have the ability to utilize transferrin through an alternative
mechanism this has negative implications for the vaccine potential of TbpA and TbpB.

II. Results
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A. MCV511 and MCV523 revert to a transferrin-positive growth phenotype at a
high frequency and only in the presence of TbpB
The frequency of spontaneous base pair changes that result in a reversion event is
approximately 10-7 to 10-8 (174). Quantifying the frequency with which MCV511
(L3HA) and MCV523 (β16HA) reverted to a transferrin-positive growth phenotype was
complicated by the fact that colonies continued to arise with increasing incubation time.
However, the rate of reversion for these strains, which was calculated to be around 10-5,
was considerably higher than the rate of spontaneous reversion. These isolates were
designated “pseudo-revertants” because the frequency with which they occur was higher
than that expected from a typical mutational reversion. However, the rate with which
MCV523 (β16HA) reverted to a transferrin-positive growth phenotype was slower than
that of MCV511 (L3HA), suggesting that these events occur through different
mechanisms. Interestingly, pseudo-reversion to a transferrin-positive growth phenotype
only occurred in the FA19 (TbpB+) background, as MCV512 (L3HA, TbpB−) and
MCV524 (β16HA, TbpB−) were never able to utilize transferrin as a sole iron source.
Based on these findings, we conclude that reversion does not occur through spontaneous
base pair changes and occurs in a TbpB-dependent manner. Since MCV511 (L3HA) and
MCV523 (β16HA) likely revert via different mechanisms, the mechanism by which
MCV511 (L3HA) reverted to a transferrin-positive growth phenotype was investigated as
described below.
B. Pseudo-revertants retain HA-encoding epitope in tbpA
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To ensure that MCV511 (L3HA) pseudo-reversion to a transferrin-positive
growth phenotype did not occur through the loss of the HA-encoding epitope, PCR
amplification of tbpA was carried out on a number of individually isolated pseudorevertants (Figure 25). FA19 served as the negative control for it contains no HAencoding epitope insertion. However, MCV511 (L3HA) and the various pseudorevertants clearly retained the HA-encoding epitope as indicated by the increased DNA
fragment size. Sequence analysis of tbpA from two individually isolated pseudorevertants was also performed. Both PCR amplification and sequence analysis confirmed
the presence of the HA-encoding epitope in these pseudo-revertant isolates. Therefore,
the MCV511 (L3HA) pseudo-reversion to a transferrin-positive growth phenotype is not
due to the loss of the HA-insertion and may occur through some other change.
C. Pseudo-revertants have no sequence changes within the tbp locus
Although the frequency of reversion was much higher than that expected for a
spontaneous base pair change, sequence analysis of tbpA and tbpB was performed with
MCV511 (L3HA) to determine if a sequence change caused the reversion to a transferrinpositive growth phenotype. Sequencing of the tbpA and tbpB coding regions was
performed using a number of tbpA- and tbpB-specific primers listed in Table 4.
Sequencing of two pseudo-revertants revealed no intragenic (tbpA) or intergenic (tbpB)
sequence changes. Therefore, MCV511 (L3HA) pseudo-reversion to a transferrinpositive growth phenotype does not involve spontaneous sequence changes in the coding
regions of either tbpA or tbpB.
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Figure 25. HA-encoding epitope is present in tbpA of pseudo-revertants. tbpA was
PCR amplified using tbpA specific oligonucleotides for detection of HA-encoding
epitopes. The shift in size indicates the presence of the HA-encoding epitope in tbpA.
Controls include MCV511 (positive control, L3HA) and FA19 (negative control).
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D. Pseudo-revertants express wild-type levels of TbpA, TbpB, and TonB
To determine if MCV511 (L3HA) reverted to a transferrin-positive growth
phenotype through changes in protein expression levels, Western blot analyses were
carried out. To assess changes in the transferrin-iron uptake system, antibodies were
used for the detection of TbpA, TbpB, and TonB (Figure 26). FA19 and MCV511
(L3HA) were used as positive controls for wild-type expression levels of TbpA, TbpB,
and TonB proteins. A number of MCV511 (L3HA) pseudo-revertants were analyzed by
Western blot and all expressed wild-type levels of TbpA, TbpB, and TonB proteins.
Therefore, MCV511 (L3HA) pseudo-reversion does not occur through sequence changes
or any changes in the expression of TonB or the transferrin binding proteins. In addition,
these data suggest that regulatory events that control protein expression of TbpA, TbpB,
and TonB are not involved in the mechanism of MCV511 (L3HA) pseudo-reversion.
E. Pseudo-revertant growth is TbpA-dependent and TonB-independent
Since MCV511 (L3HA) pseudo-reversion occurred in a TbpB-dependent manner,
we sought to determine if this mechanism was also dependent on TbpA and TonB.
Therefore, TbpA and TonB mutants were constructed in a L3HA pseudo-revertant strain,
MCV267. The TbpA knockout strain, MCV280, was generated through insertion of a
mini transposon, encoding chloramphenicol resistance, into tbpA (tbpA::mTn3cat) (Table
2 and 3). Similarly, the TonB knockout strain, MCV281, was generated through the
insertion of an omega cassette, encoding streptomycin resistance, into tonB (tonB::Ω)
(Table 2 and 3). To assess if either TbpA or TonB were required for reversion to a
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Figure 26. Pseudo-revertants express wild-type levels of TbpA, TbpB, and TonB by
Western blot. Iron-stressed gonococci were lysed and standardized to a constant cell
density. Whole-cell lysates were separated by SDS-PAGE and then transferred to
nitrocellulose membranes. Blots were probed with anti-TbpA (α-TbpA) polyclonal
antibodies (top panel), anti-TbpB (α-TbpB) polyclonal antibodies (middle panel), or antiTonB (α-TonB) polyclonal antibodies (bottom panel). Each lane is labeled according to
the strain name. Controls include FA19 (positive control, TbpA+ TbpB+) and MCV511
(positive control, L3HA, TbpB+).
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transferrin-positive growth phenotype, MCV280 (TbpA−) and MCV281 (TonB−) were
tested in transferrin-iron utilization growth assays and the phenotypes are listed in Table
10. This assay measures the ability of gonococcal strains to grow on CDM supplemented
with 30% saturated human transferrin as the sole iron source. The ability to grow
indicates an ability to utilize transferrin as a sole iron source and for this analysis
measures whether pseudo-revertant growth was dependent on TbpA or TonB. Since
MCV511 (L3HA) pseudo-reversion was dependent on TbpB, it was not surprising that
pseudo-revertant growth was also dependent on TbpA. However, it was surprising that
pseudo-revertant growth was TonB-independent (Table 10). These data suggest that
MCV511 (L3HA) reverts to a transferrin-positive growth phenotype via a TbpB- and
TbpA-dependent mechanism that bypasses the need for TonB-derived energy. This
represents the first account of a novel TonB-independent mechanism of transferrinmediated iron acquisition and suggests that N. gonorrhoeae has the ability to bypass
TonB-dependent transferrin utilization.
F. Pseudo-revertants may release a soluble factor involved in transferrin
utilization
It has been previously shown that MCV267 (L3HA pseudo-revertant) has the
ability to promote the growth of MCV512 (L3HA, TbpB−) (Yost-Daljev, unpublished
data) (Figure 27). MCV512 (L3HA, TbpB−) was incapable of growth on CDM
supplemented with 30% iron-saturated human transferrin as the sole source of iron
(CDM-Tf) and was unable to revert, presumably due to the lack of TbpB. However,
when MCV512 (L3HA, TbpB−) was plated on CDM-Tf in close proximity to MCV267
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(L3HA pseudo-revertant), as shown in Figure 27, numerous colonies arose within 24
hours. The ability of MCV512 (L3HA, TbpB−) to utilize transferrin increased over time
and colonies that arose were not pseudo-revertants in that the phenotype was not
maintained following passage. Consequently, when MCV512 (L3HA, TbpB−) colonies
were patched to CDM-Tf in the absence of MCV267 (L3HA pseudo-revertant), MCV512
was no longer able to grow, indicating that this strain did not retain the ability to utilize
transferrin as a sole iron source. Therefore, the ability of MCV512 (L3HA, TbpB−) to
utilize human transferrin was a transient phenotype, dependent upon the presence of
MCV267 (L3HA pseudo-revertant) for growth. From these data, we conclude that
MCV267 (L3HA pseudo-revertant) may secrete a soluble factor that allows MCV512
(L3HA, TbpB−) to transiently utilize human transferrin as a sole iron source.
G. Pseudo-revertant growth is PilQ- and T4SS-independent
Since the previous results suggest that MCV267 (L3HA pseudo-revertant) utilizes
transferrin through a TonB-independent mechanism and may secrete a soluble iron
chelating factor, we sought to determine the mechanism by which these events may
occur. The mechanism of TbpA-dependent, TonB-independent transferrin utilization
suggests that transferrin-derived iron is not transported through TbpA because TonBderived energy would be required. Therefore, TbpA and TbpB are likely required for
only transferrin binding, while another unidentified component participates in TonBindependent iron internalization. PilQ, the pore for pilus extrusion, or the type IV
secretion system may be involved in this mechanism of TonB-independent transferriniron acquisition. It was previously shown in N. gonorrhoeae that PilQ served as a pore
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Figure 27. Pseudo-revertants promote growth of MCV512 (L3HA, TbpB−) in
transferrin-iron utilization growth assays. Gonococcal strains were patched on CDM
agarose plates containing 30% iron-saturated human transferrin as a sole iron source.
Strains are labeled according to the strain name. The thick black line indicates the
boundary that separates MCV267 (L3HA pseudo-revertant) and MCV512 (L3HA,
TbpB−). The bottom and top panels are representative of the results observed using
different isolates of the L3HA pseudo-revertant, MCV267.
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through which heme could be internalized (37); therefore, it is possible that PilQ may
allow for transferrin-mediated iron uptake as well. In addition, the type IV secretion
system (T4SS) of many pathogens has been shown to be important for the secretion of
protein effectors and various other factors. Therefore, the neisserial T4SS may be
involved in secretion of an iron chelating molecule or iron binding protein to allow for
TonB-independent transferrin utilization. PilQ and various T4SS mutants were generated
in wild-type FA19, MCV511 (L3HA), and MCV267 (L3HA pseudo-revertant) to assess
if either the reversion event or pseudo-revertant growth were dependent on these systems
for transferrin utilization (Table 10). In transferrin-iron utilization growth assays,
MCV511 (L3HA) pseudo-reversion and MCV267 (L3HA pseudo-revertant) transferrin
utilization were not dependent on either PilQ or the T4SS components. Therefore the
mechanism of TbpA- and TbpB-dependent, TonB-independent transferrin-iron
acquisition does not require the PilQ pore for iron internalization or the T4SS for release
or uptake of possible soluble iron-chelating factors.

III. Discussion
N. gonorrhoeae does not produce any known siderophores and therefore utilizes
high-affinity, TonB-dependent iron acquisition systems to acquire iron from host ironbinding proteins. The gonococcal transferrin-iron acquisition system is important for in
vivo iron acquisition and has been linked to virulence, as it is required to initiate infection
in the human host (49). This study represents the first account of a means by which N.
gonorrhoeae bypasses TonB-dependent transferrin-iron acquisition. Interestingly, this
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Table 10. Growth phenotypes of MCV511 (L3HA) and MCV267 (L3HA pseudorevertant) derived mutants in transferrin-iron utilization assays

Strain

Phenotype

Growth phenotype

Controls
FA19
FA6905
FA6815

TbpA+, TbpB+
TbpA+, TbpB− (ΔtbpB)
TbpA−, TbpB− (tbpB::Ω)

+
+
−

FA19 derived strains
MCV269
MCV270
MCV271
MCV272
MCV273
MCV274
MCV904
MCV906

TbpA+, TbpB+, TonB− (tonB::Ω)
TbpA+, TbpB+, PilQ− (pilQ::Ω)
TbpA+, TbpB+, DsbC− (dsbC::ermC)
TbpA+, TbpB+, TraC− (traC::ermC)
TbpA+, TbpB+, TraH− (traH::ermC)
TbpA+, TbpB+, TraN− (traN::ermC)
TbpA+, TbpB+, FbpA− (fbpA::ermClacIP) −RBS
TbpA+, TbpB+, FbpA− (fbpA::ermClacIP)

−
+
+
+
+
+
−
+

MCV511 (L3HA) derived strains
MCV511
MCV512
MCV275
MCV276
MCV277
MCV278
MCV279

TbpA L3HA343, TbpB+
TbpA L3HA343, TbpB− (ΔtbpB)
TbpA L3HA343, TbpB+, PilQ− (pilQ::Ω)
TbpA L3HA343, TbpB+, DsbC− (dsbC::ermC)
TbpA L3HA343, TbpB+, TraC− (traC::ermC)
TbpA L3HA343, TbpB+, TraH− (traH::ermC)
TbpA L3HA343, TbpB+, TraN− (traN::ermC)

−
−
+
+
+
+
+

MCV267 (L3HA revertant) derived strains
MCV267
MCV280
MCV281
MCV282
MCV283
MCV284

TbpA L3HA343, TbpB+ revertant
L3HA343, TbpB+, TbpA− (tbpA::mTn3cat)
TbpA L3HA343, TonB− (tonB::Ω)
TbpA L3HA343, TbpB+, PilQ− (pilQ::Ω)
TbpA L3HA343, TbpB+, DsbC− (dsbC::ermC)
TbpA L3HA343, TbpB+, TraC− (traC::ermC)

+
−
+
+
+
+
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MCV285
MCV286
MCV287
MCV288

TbpA L3HA343, TbpB+, TraH− (traH::ermC)
TbpA L3HA343, TbpB+, TraN− (traN::ermC)
TbpA L3HA343, TbpB+, FbpA− (fbpA::ermClacIP)
−RBS
TbpA L3HA343, TbpB+, FbpA− (fbpA::ermClacIP)

+
+
−
+
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TonB-independent mechanism of transferrin-iron utilization requires TbpA and TbpB.
The wild-type transferrin-iron acquisition system functions in two major steps: transferrin
binding and iron internalization. TonB provides the energy for iron internalization but is
not necessary for transferrin binding. Therefore, in MCV267 (L3HA pseudo-revertant),
TbpA and TbpB are likely only required for transferrin binding and are unlikely to play a
role in iron uptake, for this process requires TonB-derived energy. However, HA epitope
insertion into loop 3 of TbpA prevented transferrin binding (243). Therefore, it is likely
that TbpA expressed by MCV267 (L3HA pseudo-revertant) is also unable to bind human
transferrin. Thus, these data suggest that TbpA and TbpB form a complex that is
required for transferrin utilization in a TonB-independent mechanism. As addressed in
previous chapters, wild-type TbpA and TbpB association have been demonstrated (63,
64, 97, 210), but the extent of this complex interaction has not been characterized. It
appears that even this TonB-independent mechanism requires the formation or
association of the TbpA and TbpB complex.
Although most mechanisms of iron acquisition are dependent on TonB, there have
been various TonB-independent mechanisms described. N. gonorrhoeae has been shown
to bypass TonB-dependent, HpuAB-mediated heme acquisition from hemoglobin through
a TonB-independent, PilQ-dependent mechanism (37). In addition, N. gonorrhoeae can
utilize heme in a TonB-independent process (209). Furthermore, many mechanisms of
xenosiderophore utilization have been shown to occur in a TonB-independent manner
(74, 211). The TonB-independent mechanism of xenosiderophore utilization depended
on gonococcal ferric binding protein A (FbpA) (211). FbpA has been characterized as a
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periplasmic high-affinity iron binding protein, but has also been identified in gonococcal
culture supernatants (211), which suggests that it may play a role in iron binding at the
gonococcal cell surface. Thus, TonB-independent transferrin-iron utilization observed by
MCV267 (L3HA pseudo-revertants) may involve an FbpA-dependent mechanism of
acquiring iron from human transferrin. Furthermore, although the type IV secretion
system (T4SS) does not appear to be involved, it is possible that TbpB may be released
from the gonococcal cell surface and promote growth of MCV512 (L3HA, TbpB−) or
TbpB itself may promote iron release from transferrin. In vitro, TbpB has been shown to
promote the transfer of iron from human transferrin to FbpA, which suggests that TbpB
has the ability to remove iron from transferrin, thus making it accessible (Crumbliss
unpublished data). Additionally, iron removal from transferrin may occur independent of
TbpB through an unidentified extracellular reductase. Although the specific mechanism
by which FbpA or TbpB may promote transferrin-utilization has not been determined, it
is of great importance to understand this bypass mechanism in the context of pathogenic
mechanisms of iron acquisition.
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CHAPTER 6 – SUMMARY & PERSPECTIVES
The precise mechanism by which Neisseria gonorrhoeae acquires iron from
human transferrin has not been elucidated, but these studies have provided greater insight
into this process. It has been shown that transferrin-iron acquisition system is composed
of two transferrin binding proteins, TbpA and TbpB. It has also been shown that the
TonB-dependent, outer-membrane iron transporter, TbpA, is required for transferrin
utilization, while the lipoprotein TbpB is not (4). Furthermore, it has been shown that
TbpB makes the process of iron acquisition from human transferrin more efficient (4).
TbpB is known to function in transferrin binding and discrimination (20, 50, 183, 184),
but these roles are not solely responsible for increasing the efficiency of iron uptake
through TbpA (57). The specific mechanism by which TbpA mediates iron
internalization and the involvement of TbpB in this process has not yet been determined.
The studies presented here were designed to address many of these questions and have
aided in the understanding of this complex mechanism of transferrin-iron utilization by
N. gonorrhoeae.
Models of TonB-dependent, transferrin-iron acquisition system have been
proposed and resemble TonB-dependent siderophore transporters (28, 40, 42, 43, 119,
244). However, TonB-dependent transferrin-iron acquisition differs from that of
characterized siderophore-iron acquisition for two reasons. Firstly, the siderophore
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systems transport ferric-siderophore complexes, whereas the transferrin system transports
only iron. Therefore the transferrin-iron acquisition system requires multiple steps in the
process of iron internalization: (1) transferrin binding; (2) iron removal from transferrin;
(3) iron transport across the outer membrane; and (4) apo-transferrin release. Therefore
one objective of the studies presented here was to elucidate the mechanism by which the
TbpA plug facilitates iron binding and uptake. The second major difference between
siderophore transporters and the transferrin-iron acquisition system is the involvement of
the transferrin binding lipoprotein, TbpB. Ferric-siderophore transporters do not possess
a second component for iron acquisition. The studies presented here attempt to elucidate
the involvement of TbpB in the process of transferrin-iron utilization. Taken together,
these studies have allowed us to further characterize TbpA and TbpB in the mechanism
of transferrin-iron utilization and have identified specific regions in both proteins that are
required for efficient transferrin-mediated iron uptake by Neisseria gonorrhoeae.
Additionally, a novel TonB-independent mechanism of transferrin-iron acquisition has
been described.
Analogous to TonB-dependent transporters, TbpA consists of two distinct
domains: a C-terminal β-barrel domain and an N-terminal, globular plug domain.
Previous studies have suggested that the TbpA plug domain is critical in transferrin
utilization (243); however, the specific contribution of the plug domain had not been
shown up to this point. The analyses presented here confirm that the plug domain is
critical for transferrin-iron acquisition and specifically functions in iron binding and
uptake. Mutagenesis of specific iron-coordinating residues suggests that iron is
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coordinated by the plug domain, and disruption of iron binding sites results in the
inability of gonococci to internalize iron from human transferrin. Although these
residues are critical for iron acquisition, we hypothesize that there are additional residues
involved in this process of iron internalization. Similar to the mechanism described for
TonB-dependent, BtuB-mediated vitamin B12 uptake (72), we hypothesize that TonB
interaction with the TbpA plug domain facilitates unraveling of this domain. This partial
denaturation of the globular, plug domain opens the iron binding site or sites and
facilitates traversal of iron through the outer membrane. Through this process we
propose that iron is coordinated at multiple sites and the sequential unraveling of the plug
promotes the movement of iron from one coordination site to another until iron is passed
to ferric binding protein A (FbpA) in the periplasm. This hypothesis is supported by the
in vitro recombinant protein iron binding data, whereby the TbpA plug domain binds
more iron than FbpA, which only has one iron coordination site, suggesting that the plug
binds iron in more than one site. Furthermore, the TbpA plug structural model predicts
that residues 120–122 (EYE) are positioned at the base of the plug, which supports the
idea that iron is coordinated at multiple sites and unraveling of the plug domain allows
for the traversal of iron through the β-barrel of TbpA.
Mutagenesis studies in siderophore transporters have shown that the N-terminal
plug domain is expelled from the β-barrel during siderophore transport (121), while
others have shown that it merely undergoes a rearrangement (36). If the plug domain is
tethered to the β-barrel domain and therefore unable to undergo rearrangement,
siderophore transport cannot occur (58). In the case of transferrin-iron acquisition, the
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conformational change in the TbpA plug domain is critically important and we propose
this allows for the sequential coordination of iron at multiple sites within the TbpA plug
domain. In these studies we show that disruption of one potential iron coordination site
within the TbpA plug domain prevents iron internalization from transferrin. This work
has provided further insight into the mechanism of transferrin-iron internalization and
represents the first study to demonstrate the involvement of the plug domain in iron
binding. Further mutagenesis studies are necessary to identify additional iron
coordination sites with the TbpA plug domain. In addition, iron binding studies will be
performed with recombinant TbpA plug proteins encoding mutagenized ironcoordination sites, particularly at residues 120–122 (EYE). The controversy regarding
conformational changes that occur within the plug domain needs to be addressed in the
Neisseria transferrin-iron acquisition system. Furthermore, a crystal structure of fulllength TbpA or the TbpA plug domain would greatly assist in characterizing the
mechanism of transferrin-iron acquisition mediated by TbpA.
The data presented in this work show that TbpB is also important in the
mechanism of iron acquisition from transferrin and new functional domains within this
protein have been identified. It has been shown that TbpB specifically and independently
binds human transferrin. This lipoprotein also has the ability to discriminate between
apo- and holo-transferrin, with a preference for the iron-loaded form. TbpB increases the
efficiency of iron acquisition, but the mechanism by which it does so has not been
characterized. The studies presented here have identified a specific domain in TbpB that
contributes to increasing the efficiency of transferrin-mediated iron acquisition. This C-
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terminal double cysteine region may be important in destabilization and subsequent
removal of iron from transferrin. It has been demonstrated that wild-type TbpB, in the
absence of TbpA, can promote in vitro destabilization of human transferrin that results in
iron release (Crumbliss unpublished data) and the double cysteines may play a role in this
process. The ability of TbpB to preferentially bind holo-transferrin and the proposed
ability to remove iron from transferrin may be the qualities that allow for increased
efficiency in transferrin-mediated iron internalization. Further studies are necessary to
identify the specific function of these residues and their contributions in transferrinmediated iron acquisition by the wild-type, neisserial transferrin receptor of N.
gonorrhoeae.
Combined mutagenesis of the neisserial transferrin binding proteins has revealed
the complexity of interactions and cooperation between TbpA and TbpB in the process of
transferrin-iron internalization. From these studies, it is clear that specific domains of
TbpA and TbpB provide different functions in the internalization of iron from transferrin.
The ability of TbpB to compensate for TbpA-defective mutants has allowed us the
opportunity to investigate the domains of TbpB that share some functional redundancy
with TbpA. The TbpA and TbpB combined mutagenesis presented here has provided
insight into the compensatory functions provided by TbpB, and further investigation may
reveal additional functional properties of TbpB.
Many studies, including those presented here, have revolved around defining the
mechanism of TonB-dependent transport in Gram-negative bacteria. As described in the
introduction, bacterial pathogens depend on a large number of TonB-dependent systems
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for nutrient and iron acquisition during infection. TbpA and TbpB are the characterized
neisserial transferrin binding proteins and mediate TonB-dependent iron acquisition from
human transferrin. The studies presented here are the first to describe a TonBindependent mechanism of transferrin-iron uptake mediated by gonococcal TbpA and
TbpB. The ability of gonococci to bypass the need for TonB-derived energy in
transferrin-mediated iron transport is important in the context of all mechanisms of
TonB-dependent transport utilized by N. gonorrhoeae. Furthermore, the ability of
pathogenic bacteria to bypass TonB-dependent systems of iron acquisition is significant
in understanding the evolution of bacterial pathogens as they continue to compete for iron
within the human host.
Overall, investigation of the mechanism of transferrin-iron acquisition mediated
by TbpA and TbpB is important because it represents a novel mechanism of TonBdependent iron acquisition. Further investigation is necessary to fully characterize each
step in this process of TonB-dependent transferrin-iron acquisition. Additionally, the
novel mechanism of TonB-independent transferrin utilization needs to be further
characterized and is currently being evaluated in regard to the contribution of FbpA in
this process.
TbpA and TbpB are prospective vaccine candidates because these proteins are
expressed by all gonococcal isolates (138). In addition TbpA and TbpB are not subject to
phase or antigenic variation like many of the other virulence factors of N. gonorrhoeae.
Most importantly, TbpA and TbpB are required to initiate infection in male volunteers
(49). Therefore, characterization of TbpA and TbpB is important in looking at these
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proteins as potential vaccine candidates. It has been shown in the closely related N.
meningitidis, antibodies raised against the transferrin binding proteins are cross-reactive,
bactericidal, and have the ability to block transferrin binding (53, 187, 233).
Furthermore, it was recently shown that antibodies raised against recombinant
gonococcal transferrin binding proteins are also cross-reactive and bactericidal (176,
177). Taken together these data suggest that the components of the neisserial transferriniron uptake system are promising candidates for an effective vaccine against Neisseria
infections. Therefore identification of novel targets within TbpA and TbpB could aid in
the future development of vaccines and new antimicrobials.
The plug domain of TbpA is of particular interest due to the important role it
plays in transferrin-iron acquisition. This domain has been shown to be surface exposed
(243) and antigenic. Additionally, it is highly conserved among bacterial pathogens,
expressing the transferrin binding proteins. Thus, the plug domain of TbpA could serve
as a new target for antimicrobial or vaccine development, and due to the high
conservation of the plug domain, treatments may be cross protective for a number of
bacterial pathogens.
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